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ABSTRACT 
 
Investigating Hemodynamic Responses to Electrical Neurostimulation 
 
Sean Youra 
 
Since the 1900s, the number of deaths attributable to cardiovascular disease has 
steadily risen. With the advent of antihypertensive drugs and non-invasive surgical 
procedures, such as intravascular stenting, these numbers have begun to level off. Despite 
this trend, the number of patients diagnosed with some form of cardiovascular disease has 
only increased. By 2030, prevalence of coronary heart disease is expected to increase 
approximately by 18% in the United States. By 2050, prevalence of peripheral arterial 
occlusive disease is expected to increase approximately by 98% in the U.S. No single 
drug or surgical intervention offers a complete solution to these problems. Thus, a multi-
faceted regimen of lifestyle changes, medication, and device or surgical interventions is 
usually necessary. A potential adjunct therapy and cost-effective solution for treating 
cardiovascular disease that has been overlooked is neurostimulation.  
Recent studies show that using neurostimulation techniques, such as 
transcutaneous electrical nerve stimulation (TENS), can help to reduce ischemic pain, 
lower blood pressure, increase blood flow to the periphery, and decrease systemic 
vascular resistance. The mechanisms by which these hemodynamic changes occur is still 
under investigation. The primary aim of this thesis is to elucidate these mechanisms 
through a thorough synthesis of the existing literature on this subject. Neurostimulation, 
specifically TENS, is thought to modulate both the metaboreflex and norepinephrine 
release from sympathetic nerve terminals.  
To test the hypothesis that TENS increases local blood flow, decreases mean 
arterial pressure, and decreases cutaneous vascular resistance compared to placebo, in 
which the electrodes are attached but no electrical stimulation is applied, a protocol was 
developed to test the effect of neurostimulation on healthy subjects. Implementation of 
this protocol in a pilot study will determine if neurostimulation causes significant changes 
in blood flow using the most relevant perfusion measurement instrumentation. Before 
conducting this study, pre-pilot comparison studies of interferential current therapy (IFC) 
versus TENS, low frequency (4 Hz) TENS versus high frequency (100 Hz) TENS, and 
electrode placement on the back versus the forearm were conducted. The only 
statistically significant difference found was that the application of IFC on the back 
decreased the reperfusion time, meaning that the time required to reach the average 
baseline perfusion unit value after occlusion decreased. Further pre-pilot work 
investigating these different modalities and parameters is necessary to ensure that 
favorable hemodynamic changes can be detected in the pilot study.  
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CHAPTER 1 – INTRODUCTION 
1.1 Motivation 
1.1.1 Peripheral Arterial Occlusive Disease 
 Peripheral arterial occlusive disease (PAOD) affects 8 to 12 million Americans, 
which is expected to increase to about 19 million by 2050 [1-3]. PAOD affects patients 
greater than 65 years of age significantly more than younger patients (Figure 1.1).  
 
Figure 1.1: Prevalence of large-vessel PAOD (LV-PAD) in American patients among 
selected age groups [4] 
PAOD is one of three serious forms of ischemic disease; the other two are 
cerebrovascular disease (CVD) and coronary artery disease (CAD). Ischemic disease is 
responsible for more deaths in the United States than any other condition [5].  
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 The etiology behind all these forms of ischemic disease is atherogenesis, whereby 
plaque builds up in the artery wall causing it to thicken, which eventually manifests itself 
as atherosclerosis, i.e. mature, vulnerable plaques and stiffening of the vessel wall. 
Atherogenesis is a positive feedback mechanism induced by turbulent shear stresses 
within the arteries, usually at bifurcation points. Normally, changes in laminar shear is 
resolved by outward or inward vessel remodeling. However, turbulent shear cannot be 
adequately resolved at these bifurcation points, which continually activates the 
endothelium, i.e. the shear induces a proinflammatory and procoagulant state. The 
activation of the endothelium causes endothelial cells (ECs) to separate, express adhesion 
proteins, such as intercellular adhesion molecule-1 (ICAM-1), and secrete cytokines, 
such as monocyte chemoattractant protein-1 (MCP-1). MCP-1 triggers migration of 
leukocytes into the intima and ICAM-1 binds the leukocytes to the ECs. These 
leukocytes, specifically monocytes, mature into macrophages that phagocytose lipids, e.g. 
low-density lipoproteins (LDLs) in the subendothelial space. After ingesting enough 
LDLs, the macrophages transform into foam cells, which activate T-helper cells that 
secrete interferon-γ (INF-γ) and tumor necrosis factor-α (TNF-α), both of which activate 
the endothelium. In addition, TNF-α causes proliferation of smooth muscle cells (SMCs) 
into the intima [6]. The proliferation of SMCs is one of the few events in this whole 
cellular cascade that seems to have more of a reparative effect. Once in the intima, SMCs 
produce matrix proteins, such as collagen and elastin, that contribute to the formation of 
the fibrous cap over the plaque, providing structural stability to the lesion and reducing 
the chance of it rupturing. Plaque mainly consists of calcium hydroxyapatite, 
microvasculature, fibrous tissue, cholesterol, and fats, as well as inflammatory cells, such 
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as T cells and macrophages, at the periphery of the plaque. Plaque composition and size 
will eventually determine clinical prognosis for PAOD patients i.e. the smaller the size 
and the more stable the plaque, the less severe the disease tends to be [7]. Over time, 
plaque buildup changes the properties and physical appearance of the artery, as illustrated 
in Figure 1.2. 
 
Figure 1.2: Progression of atherosclerosis. Early atherosclerosis characterized by 
increased plaque buildup within the vessel. Advanced atherosclerosis characterized by 
proliferation of smooth muscle into the tunica intima, thickening of the tunica media, and 
narrowing of the lumen [8] 
In the case of PAOD and other ischemic diseases, endogenous revascularization is 
impaired, i.e. arteriogenesis and angiogenesis, as well as vasodilation of the collateral 
vessels [6]. The walls of the artery begin to harden and blood flow is impeded as the 
condition worsens, causing ischemia and hypoxia. If exacerbated through continual 
endothelium activation, thrombus formation may occur. Eventually, a myocardial 
infarction (MI) or stroke may occur if the thrombus detaches from the vessel wall and 
becomes an embolus that reaches the heart or brain, respectively. Both an MI and stroke 
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can cause immediate death; even if they do not, the lifespan of the individual will be 
drastically shortened.  
The symptoms of atherosclerosis may remain silent until there is a significant 
reduction in blood flow. If this occurs in the heart, symptoms such as angina pectoris and 
shortness of breath tend to develop. Worsening angina pectoris, especially at rest, may 
signal an imminent MI. If this occurs in the brain, a number of motor and neurological 
problems may result, such as speech deterioration, breathing difficulty, and bladder 
incontinence. As blood flow is further impeded, a stroke can occur, potentially causing 
significant brain damage. If this occurs in the peripheral limbs, claudication is the most 
common symptom, although many patients do not report this to their physician. 
Claudication makes exercise and even normal daily activity difficult because of the 
ischemic pain. Atherosclerosis may also occur in the kidneys i.e. ischemic nephropathy, 
causing a host of symptoms such as uremia, dyspnea, hypertension, and kidney atrophy. 
If hypoperfusion occurs in both kidneys, it may lead to renal failure. There are a number 
of risk factors associated with ischemic disease including lack of exercise, poor nutrition, 
smoking, hypertension, diabetes, obesity, and a family history of heart disease [5]. 
1.1.2 Treatments 
The first-line treatment option against ischemic disease is usually lifestyle 
changes. A patient’s diet can be carefully controlled by limiting their intake of calories, 
fat, and sodium, so that blood pressure is reduced. Frequently, medication may also be 
prescribed to lower cholesterol levels. Cholesterol medication includes statins, niacin, 
bile-acid resins, fibric acid derivatives, and cholesterol absorption inhibitors. Many of 
these lower LDL and triglyceride levels while slightly raising HDL levels [9]. The 
rationale behind this is that lowering LDLs should cause less endothelial activation and 
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raising HDLs should increase reverse cholesterol transport, whereby HDLs remove lipids 
from the surface of foam cells and transport them to the liver for processing [6]. Statins 
are the most commonly prescribed cholesterol medications to treat atherosclerosis, 
because they reduce all-cause mortality by about 14% and major adverse cardiac events 
by more than 20% [10]. Other lifestyle changes include smoking cessation and a regular 
exercise regimen that includes aerobic and resistance training, both of which can improve 
pain-free walking distance in patients with PAOD [3, 11]. In fact, under direct 
supervision, maximal walking distance may improve by an estimated 120% compared to 
before the start of the exercise training program [12]. The mechanisms behind this 
improvement in walking distance are attributed to enhanced vaso-responsiveness, 
angiogenesis, and arteriogenesis [13, 14].  
The advent of antihypertensive drugs has vastly improved our ability to control 
many of the symptoms associated with atherosclerosis. Numerous variants of such drugs 
exist on the market today including diuretics, adrenergic inhibitors such as beta-blockers, 
angiotensin-converting-enzyme (ACE) inhibitors, and calcium channel blockers. 
Diuretics have been prescribed for decades and are considered the “gold standard” of 
antihypertensive drugs. Diuretics inhibit sodium and chloride reabsorption, which 
decreases extracellular fluid volume, cardiac output, and peripheral vascular resistance. 
In this way, they offer protection against myocardial infarction (MI), stroke, and heart 
failure [15]. Beta-blockers suppress over-activity of the sympathetic nervous system 
(SNS) by inhibiting beta-adrenergic norepinephrine receptors, which in turn reduces heart 
rate (HR), cardiac output (CO), and blood pressure (BP). This is especially important for 
both older individuals and PAOD patients who have an overactive SNS [16]. ACE 
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inhibitors block the synthesis of angiotensin II in the renin-angiotensin system. Normally, 
renin is converted into angiotensin I via angiotensinogen, and then subsequently 
angiotensin I is converted into angiotensin II via ACE. Angiotensin II is a potent 
vasoconstrictor, so ACE inhibitors reduce vasoconstriction [15]. They are commonly 
prescribed to congestive heart failure (CHF) patients to lower mean arterial pressure 
(MAP) and decrease systemic vascular resistance (SVR), and diabetic renal disease 
patients to increase renal blood flow and sodium excretion rates, which improves renal 
functioning [17, 18]. Calcium-channel blockers cause vasodilation by blocking L-type 
calcium channels on arterial SMCs, which decreases BP, especially in the case of 
hypertension. Calcium-channel blockers may also be combined with beta-blockers for 
enhanced cardioprotective effects by further increasing blood flow and reducing BP [15].  
As the disease progresses, a more aggressive surgical procedure may be needed. If 
the plaque buildup is limited to one particular area, then balloon angioplasty combined 
with stenting is commonly used. In this procedure, a balloon-tipped catheter is inserted 
into the femoral artery and guided to the area of interest. The balloon is then inflated, 
pushing the plaque up against the walls of the artery, which helps to improve blood flow 
in the region by temporarily relieving stenosis. Another balloon with a mounted stent is 
guided to the blockage and expanded in the same way. The stent is a permanent fixture 
that is used to prevent elastic recoil of the vessel wall. The basic surgical procedure is 
shown in Figure 1.3.  
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Figure 1.3: A longitudinal section view of the insertion of a stent within an artery 1) 
Balloon and stent are guided to the plaque location using a catheter guidewire 2) The 
balloon is inflated expanding the stent and pushing the plaque up against the vessel wall 
3) After deflating the balloon and removing the catheter, the stent remains in place and 
integrates with the host tissue over time [19] 
The advantage of this procedure is that it is minimally invasive, so the recovery time and 
risk associated with the procedure are significantly reduced. However, there are many 
cases in which angioplasty and stenting may not be a viable option. For example, if there 
are multiple sites of blockage, if the artery itself it too small, or if there is a complete 
blockage in the region, then peripheral artery bypass surgery may be necessary. 
Peripheral artery bypass utilizes autologous, healthy functioning vessels, commonly the 
great saphenous vein, or a synthetic graft such as Dacron or PTFE, to create a detour 
around the blockage, as can be seen in Figure 1.4 [20]. Higher patency rates, i.e. 
unobstructed and open vessel lumens, are typically seen when autologous vein grafts are 
used compared to synthetic grafts [21]. As compared to angioplasty and stenting, this 
procedure is much more invasive and expensive [22], but is associated with lower 
amputation rates and higher survival rates [20].  
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Figure 1.4: Peripheral artery bypass circumvents the occluded areas within the lower 
extremities, allowing blood to reach the tissue downstream of the blockage [23] 
 All treatments available for atherosclerosis have limited efficacy, especially long-
term. In the case of lifestyle changes, such as exercise, the progression of the disease may 
be slowed and the quality of life may be improved, but in more severe cases, such as 
critical limb ischemia, this may have little to no effect [21]. Statins carry many possible 
side-effects including memory loss, liver damage, and hyperglycemia [9]. Both diuretics 
and beta-blockers may cause insulin resistance, while calcium-channel blockers, 
specifically Nifedipine, may provoke myocardial ischemia from reflex tachycardia [15]. 
Not only are peripheral bypass grafts more invasive and expensive than angioplasty and 
stenting, but they also exhibit lower patency rates and higher reintervention rates [24], 
hence stenting is now more commonly used in hospitals across the U.S. [25]. However, 
even with stenting, there is a risk of possible infection at the catheter insertion site and 
restenosis with bare-metal stents (BMS) [26]. The restenosis issue has been partially 
ameliorated with the advent of drug-eluting stents (DES) that prevent restenosis [27]. 
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Specifically, paclitaxel-eluting stents exhibit the lowest vascular restenosis [28, 29], but 
in-stent thrombosis is actually higher with DES following the removal of anti-platelet 
agents compared to BMS [30, 31]. Because all current treatments suffer from various 
inadequacies, novel treatment options must be explored and implemented.  
As an adjunct to these treatments, neurostimulation may be used to treat the 
symptoms of ischemic disease, specifically the pain caused by ischemia. Although 
neurostimulation has been primarily used to treat chronic pain, such as low back pain, 
many studies now suggest that it may also reduce ischemic pain by increasing blood flow 
and restoring the oxygen supply to the affected area [32-37]. The mechanisms of these 
effects are poorly understood, mainly because there is more than one process at work. 
The neurostimulation technique, stimulation parameters, and patient selection all 
influence the changes in blood perfusion. Nonetheless, the changes in SVR, BP, and 
perfusion have potentially large implications for patients suffering from ischemic 
diseases. For example, if neurostimulation can decrease vascular resistance and blood 
pressure while maintaining adequate blood flow throughout the body, the workload on 
the heart will be reduced and the condition may be prevented from worsening. Another 
potential application of neurostimulation could be saving severely ischemic limbs from 
being amputated by restoring some blood flow to the limbs. Thus, it would be worthwhile 
to investigate whether neurostimulation can provide reliable analgesic, anti-ischemic 
benefits to these affected patients.  
1.2 Neurostimulation 
 Neurostimulation uses electrodes to stimulate excitable biological tissue, which in 
turn modulates some part of the nervous system. Neurostimulation is the cornerstone of 
neural engineering (neuroengineeering) and encompasses three subfields: 
10 
 
neuromodulation, stereotactic and functional neurosurgery, and functional electrical 
stimulation (FES) [38]. Neuromodulation acts directly upon specific nerves or regions of 
the brain by sending electrical, chemical, or optical signals via implantable, or non-
implantable, devices, which are used to treat neural disorders, including sensory and 
motor disorders. Examples of such devices include spinal cord stimulators, deep brain 
stimulators, and peripheral nerve stimulators, transcranial magnetic stimulators, and 
implanted intraspinal drug delivery pumps [39]. About a century ago, neurosurgery 
primarily entailed the ablation of damaged or dysfunctional nervous tissue to treat 
nervous system disorders, such as Parkinson’s, epilepsy, and tremors, pain from spinal 
disc herniation, injuries of the peripheral nerves, spinal cord or head trauma, and 
psychiatric illnesses, but electrical neurostimulation is now more commonly used to treat 
these disorders. However, neurosurgery may still selectively be used depending on the 
patient criteria and if the patient presents any contraindications for the particular 
neurostimulation device. FES pertains mostly to restoring some function in the limbs 
following injury or ischemia by selectively stimulating the damaged nerves; this subfield 
also focuses on auditory and visual prostheses [38]. Because neuromodulation and FES 
are used for similar applications, the two terms are commonly used interchangeably, but 
the procedures involved in terms of leads and electrode placement do differ. Throughout 
the course of this thesis, the term “neurostimulation” will be used to refer specifically to 
neuromodulation that utilizes electrical impulses rather than neurosurgery or FES.  
 There are many neurostimulation techniques available today, and most focus on 
pain management. Some of the most common methods are transcutaneous electrical 
nerve stimulation (TENS), spinal cord stimulation (SCS), electroacupuncture (EA), and 
 11 
 
interferential current stimulation (IFC), all of which will be discussed in much greater 
detail in Chapter 2. To effectively manage and reduce the patient’s pain, certain 
parameters must be carefully adjusted to provide the maximum analgesic benefits. These 
parameters include stimulus intensity, pulse width, and frequency. The intensity is the 
relative strength of the stimulation, measured in milliamps (mA) or volts (V) based on the 
stimulation unit design, i.e. a constant current unit provides variable voltage to maintain 
the current and outputs intensity in mA, while a constant voltage unit provides variable 
current to maintain the voltage and outputs intensity in V. This is the most variable 
parameter, since the intensity range varies among different stimulation units. Electrode 
placement is the main factor driving these difference,s e.g. different intensities will be 
required for treating chronic back pain depending on whether the electrodes are applied 
on the surface of the skin or implanted within the epidural space of the spinal cord. There 
is considerable individual variation with intensity as well, because of differences in 
sensory and motor thresholds, so this parameter should be first adjusted by the physician 
to avoid any pain or discomfort. The intensity “feeling” will be strongly influenced by 
both the pulse width and frequency. Pulse width is the duration of a pulse, measured in 
microseconds (µs). This parameter usually ranges between 100 and 400 µs. Frequency is 
the rate the pulses are transmitted, measured in hertz (Hz, cycles per second). A range of 
20 to 120 Hz is common for this parameter, although much higher frequencies may be 
used for SCS for improved paresthesia, but this comes with the cost of higher power 
requirements [38, 40]. The lowest possible settings for all these parameters are usually 
chosen to conserve battery life, especially in the case of implanted stimulators [38]. 
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Comprehension of the gate control theory is required to understand how 
neurostimulation elicits an analgesic effect. The gate control theory was first published 
by Ronald Melzack and Patrick Wall in 1965. Before this time, there were two mutually 
exclusive theories, the specificity theory and the pattern theory, both of which attempted 
to explain the mechanisms underlying pain. The specificity theory stated that pain is very 
similar to vision or hearing in that it has its own specific central and peripheral neural 
pathways; these pathways are direct “transmission lines” without modulation from any 
other systems [41]. According to this theory, a nociceptor would only be activated by 
noxious stimuli and the signal would then travel along a pain fiber up to specific “pain 
centers” in the brain. Large afferent fibers were responsible for touch sensations while 
small afferent fibers were responsible for pain sensations. Evidence for this theory comes 
from Schiff and Woroschiloff’s work in which they transected the grey matter, which 
effectively eliminated painful sensations but not touch. Similarly, they transected the 
posterior white matter, which eliminated touch sensations but not pain [42, 43]. The 
specificity theory continued to evolve when Sherrington provided a framework for the 
specificity of neurons to touch, temperature, and pain, and described how receptors lower 
the excitability threshold for a given stimulus and raise it for others. This inadvertently 
resolved the disparity between the specificity theory and the intensity theory, another 
popular pain theory of the time, which stated that pain resulted from excessive 
somatosensory stimulation [43, 44]. The pattern theory, as proposed by Nafe, stated that 
sensation occurs as a result of specific patterns of neural firing. The stimulus type and 
intensity is encoded in the “spatial and temporal profile”, i.e. where the stimulus occurs 
and the duration of the stimulus. This theory was substantiated by Weddell and Sinclair’s 
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work who observed that intense stimulation of various nerve fibers would all cause the 
sensation of pain [43, 45, 46]. A depiction of both the pattern theory and the specificity 
theory is shown in Figure 1.5. 
 
 
  
 
 
 
 
 
 
 
Figure 1.5: Schematic diagrams of both the pattern theory and specificity theory. In the 
pattern theory, nonspecific receptors in the skin respond to both noxious and innocuous 
stimuli, which are transmitted to the dorsal root ganglion (DRG) neurons, each of which 
has different levels of responsiveness to stimuli; the pattern of firing determines the 
stimulus type. In the specificity theory, each stimulus type is encoded in its own unique 
pathway e.g. a noxious stimulus is transmitted to DRG nociceptors and then to dorsal 
horn nociceptive neurons [43] 
However, each theory had substantial weaknesses in that they could not 
adequately explain the mechanisms behind certain pathological pain states, such as 
phantom limb pain or peripheral neuralgias, i.e. sharp pain due to irritation or injury of a 
nerve. The specificity theory assumed that a “pain receptor” must only sense pain and 
that there is a specific brain center that deals only with pain. Although it is true that Aδ-
fibers respond to high intensity stimulation such as sharp pain, these fibers also respond 
to thermal and mechanical stimuli [47]. Similarly, there are many regions in the brain and 
spinal cord, such as the dorsal horn, thalamus, periaqueductal grey (PAG), parabrachial 
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area (PB), and rostral ventromedial medulla (RVM), that modulate and control the 
sensation of pain, not one single center [48, 49]. The most glaring limitation with Nafe’s 
pattern theory was his assumption that all fibers were alike and any type of stimulus 
would activate nonspecific receptors; however, there is a high degree of specialization 
between receptors and fibers [50, 51]. For example, activation of transient receptor 
potential vanilloid receptor-1 (TRPV1), through the application of heat, selectively 
activates C-fibers [47, 52]. Although reasonably sound, both theories still lacked unity 
and could not adequately explain the etiology behind many neuropathies and variations in 
pain sensation. This limitation was addressed by the gate control theory.  
The gate control theory basically unites the specificity theory and the pattern 
theory by stating there are specific fibers and receptors, but there is also a “control 
center” that modulates all somatosensory stimuli before an individual experiences a 
sensation. This “control center” or gate control system is the substantia gelatinosa (SG) in 
the dorsal horn of the spinal cord, as illustrated in Figure 1.6.  
. 
Figure 1.6: Cross-section of the spinal cord at the cervical level depicting the various 
tracts and regions; the substantia gelatinosa is located within the dorsal horn (upper 
right) [53] 
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The SG modulates incoming nerve impulses before the impulse reaches the first central 
transmission cells (T cells). Neurons in the SG have an inhibitory effect on the primary 
afferent terminals of the T cells. This inhibitory effect is enhanced by increased activity 
from Aα-fibers and Aβ-fibers and reduced by increased activity from Aδ-fibers and C-
fibers [43]; depictions of these various fiber types are shown in Figure 1.7.  
 
Figure 1.7: Average diameters and conduction velocities for primary afferent neurons; 
more myelination increases conduction velocity [54] 
Aβ-fibers have low activation thresholds and transmit tactile information. Both Aδ-fibers 
and C-fibers have high activation thresholds and transmit nociceptive information, which 
may originate from thermal, chemical, or mechanical noxious stimuli [47]. C-fibers are 
associated with longer, throbbing pain while Aδ-fibers are associated with fast, sharp 
pain. In the absence of a stimulus or from activation of Aβ-fibers, the gate remains 
“closed”, i.e. pain perception does not occur, because the inhibitory effect dominates and 
prevents activation of the T cells. The activation of C-fibers causes the gate to “open”, 
i.e. pain perception does occur, because the inhibitory effect is reduced, which activates 
the T cells, allowing the noxious stimulus to reach the “action system” that is responsible 
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for painful sensations and responses. If the noxious stimulus intensity increases, the firing 
of the T cells increases slowly. If this stimulus is prolonged, the Aβ-fibers begin to adapt 
while C-fiber activity continues to increase, further increasing the firing of the T cells 
[41]. A depiction of how this gate control system works is shown in Figure 1.8. 
 
Figure 1.8: Schematic of the gate control system where A-fibers and C-fibers innervate 
the SG and first central transmission (T) cells. The SG inhibitory effect on the T cells is 
influenced by the relative activities of the A-fibers and C-fibers. This, combined with 
central control mechanisms, leads to some sensory and response output by the action 
system [43] 
 Our understanding of pain mechanisms has changed since the gate control theory 
was first proposed, yet many of its tenets and assumptions hold true. For example, we 
now know where each fiber type terminates in the different grey matter layers of the 
dorsal horn, i.e. the Rexed laminae of the dorsal horn. Both Aδ-fibers and C-fibers 
terminate in laminae I, II and V, while Aβ-fibers terminate in laminae III – V [49]. 
Within the dorsal horn, various neuron types exist. Nociceptive-specific (NS) neurons 
synapse with Aδ-fibers and C-fibers, proprioceptive neurons synapse with Aβ-fibers, and 
 17 
 
wide dynamic range (WDR) neurons synapse with all three fiber types. The frequency of 
action potentials elicited from WDR neurons is dependent upon the intensity of the 
stimulus, so that a noxious stimulus may be differentiated from a non-noxious stimulus 
based on the rate of firing of WDR neurons, i.e. noxious stimuli elicit higher rates of 
firing from WDR neurons. In addition, excitatory and inhibitory interneurons exist in the 
dorsal horn. The inhibitory interneurons release gamma-aminobutyric acid (GABA), 
which decreases the activity of NS and WDR neurons [47]. The excitatory interneurons 
primarily release glutamate, which increases activity of post-synaptic spinal neurons. 
Specifically, it causes depolarization of a-amino-3-hydroxy 5-methyl-4-
isoxazeloproprionic acid (AMPA) receptors, N-methyl-D-aspartate (NMDA) receptors, 
and G-protein coupled metabotropic receptors, all of which are targets for current drug 
and other therapeutic interventions [47, 55-57]. We also know that the “action system” 
that Melzack and Wall described is in fact different regions of the brain that also serve as 
“control centers” for pain modulation. For example, neurokinin I (NK1)-expressing 
neurons from lamina I, i.e. NS neurons, synapse in the thalamus, PAG, PB, and RVM 
[49]. Descending pathways, such as from the RVM, project back to the dorsal horn, 
which is where the effect of “central control” occurs [48], although these descending 
pathways are not activated without sufficient stimulation from afferent fibers. The limbic 
system is responsible for the emotional experience associated with pain, which affects the 
descending pathways and the response of the spinothalamic tract (STT) neurons. 
Projection neurons from laminae III – VI, i.e. WDR neurons, synapse primarily with the 
thalamus and provide the majority of the sensory information that reaches the brain. From 
the thalamus, somatosensory information travels to the cortex where various regions may 
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be activated depending on the stimulus [47]. The anatomical projections of the primary 
afferent fibers and their associated innervation sites are shown in Figure 1.9.  
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Figure 1.9: Diagram of how somatosensory information travels from the periphery to the 
brain.  All fibers travel up through the dorsal root ganglion (DRG) and synapse at the 
dorsal horn within different laminae as well as with the wide dynamic range (WDR) 
neurons; only C-fibers and Aδ-fibers synapse with nociceptive specific (NS) neurons. 
Projection neurons, shown as black arrows, innervate the periaqueductal grey (PAG), 
parabrachial area (PB), and thalamus. Descending pathways, shown as yellow arrows, 
project from the rostral ventromedial medulla (RVM) and other brainstem regions to the 
dorsal horn [47] 
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The strength of the modern version of the gate control theory is that it can explain 
the mechanisms of many different neuropathies and provides a framework for potential 
therapies. In the case of hyperalgesia or allodynia, “central sensitization” occurs when the 
STT neurons become hyperexcitable, so that a noxious stimulus is amplified or a non-
noxious stimulus evokes pain [58]. Central sensitization is thought to occur from the 
activation of NMDA receptors on WDR neurons by intense stimulation of C-fibers 
through the release of glutamate and substance P. This depolarization temporarily 
eliminates the Mg2+ block on the NMDA receptors, making the WDR neurons more 
responsive to Aβ-fiber stimulation [58]. Tissue inflammation involves both central 
sensitization and “peripheral sensitization”, where the sensitivity of C-fiber nerve 
terminals increases from the release of histamine, prostaglandins, and other mediators, 
and this increased sensitivity is responsible for triggering the spinal hyperexcitable state  
[59]. In chronic inflammatory diseases, the central sensitization can be sustained 
indefinitely as long as the noxious stimulus is present [60]. Nerve injury, from phantom 
limb pain, causalgia, diabetic nephropathy, etc., causes ectopic discharge at the site of 
injury, in the DRG, and from collateral sprouts of adjacent afferents, specifically within 
the cell bodies, i.e. somas, and the axons of the neurons [61]. Aδ, Aβ, and C-fibers can all 
develop ectopic discharge, which evokes central sensitization, leading to allodynia [58]. 
This explains why amputee patients may feel pain in their residual limb if pressure is 
applied. Descending pathways from the brain counteract this hyperexcitability of dorsal 
horn neurons by releasing neurotransmitters, mainly serotonin and norepinephrine, both 
of which are associated with anti-nociception. Many antidepressant drugs, such as 
tricyclic antidepressants (TCAs) and serotonin-norepinephrine reuptake inhibitors 
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(SNRIs), reduce the reuptake of one or both of these neurotransmitters, and thus can be 
used for analgesic purposes as well [47, 62]. The activity of different brain regions can 
also be modulated through psychological interventions, e.g. hypnosis or cognitive 
behavioral therapy can reduce the pain sensation by influencing cognitive control from 
the cerebral cortex and limbic system [43]. Most importantly, electrotherapy, specifically 
neurostimulation, can be used to reduce chronic pain symptoms. As stated before, the 
gate control theory explains how a noxious stimulus carried by Aδ-fibers and C-fibers 
reaches the brain by overcoming the inhibitory effect of the dorsal horn interneurons and 
activating the projection neurons. Neurostimulation uses electrodes that directly stimulate 
the Aβ-fibers through electrical impulses, which blocks the noxious stimulus carried by 
the C-fibers, such that the inhibitory effect of the dorsal horn interneurons is enhanced, 
preventing the projection neurons from firing; the end result is analgesia. 
1.3 Overview and Aims of the Thesis 
 Neurostimulation may offer yet another treatment option for patients suffering 
from ischemic disease. It possesses several advantages over current treatment methods 
including cost-effectiveness, ease of use, no major side-effects if applied correctly, non-
invasiveness (for certain modalities), less of a need for oral medication such as 
analgesics, and potential for long-lasting effectiveness. However, much is still to be 
learned about how this stimulation actually causes hemodynamic changes. Moreover, the 
results from multiple studies involving neurostimulation and its effects on blood flow are 
conflicting [32, 36, 63-68]. To date, there is no real consensus on which neurostimulation 
technique offers the best treatment, mainly because the parameters used differ widely 
throughout the literature and most studies have not focused on direct comparisons for 
different disease states. Also, large-scale, multicenter studies have been conducted on 
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individuals experiencing chronic pain and ischemic pain, and have found significant 
reductions in both using these different stimulation techniques, but have not investigated 
how the hemodynamics change [69-73].  
 In terms of hemodynamics, blood flow is the most sensitive and most difficult 
parameter to measure. The modality that is used to measure blood flow, calibration of the 
equipment, location of measurement, environmental conditions, investigator’s skill with 
the equipment, and software that is used to acquire the data may all impact the results of 
the study. The application itself may warrant the use of a specific modality, such as 
measuring cutaneous blood flow in the periphery versus measuring myocardial perfusion. 
However, there are no formal guidelines established for what perfusion instrumentation 
works most effectively for a given application.  
 This thesis will take the first steps toward bridging the gap between palliative 
neurostimulation and hemodynamic changes. By uncovering the mechanisms underlying 
these changes, and the set of parameters that produce the greatest favorable changes, 
neurostimulation units can be utilized more efficiently to maximize the analgesia and 
minimize ischemia. A pilot study in healthy humans will test the hypothesis that 
neurostimulation provides ischemic relief through increases in cutaneous blood flow and 
evokes systemic changes, such as lowering blood pressure, using the most “ideal” 
neurostimulation technique and perfusion measurement instrumentation.  
 The specific aims of this thesis are as follows: 
 Aim 1: Outline the possible mechanisms of neurostimulation- induced 
hemodynamic changes, i.e. vasodilation and reduced metaboreflex, and 
formulate a hypothesis to test these changes 
 23 
 
 Aim 2: Develop a protocol for a non-significant risk study in healthy 
volunteers 
 Aim 3: Optimize the study design through pre-pilot experiments 
In conclusion, this thesis will provide background to perform a pilot study where 
neurostimulation is applied to measure both hemodynamic endpoints and ischemic pain. 
Before outlining the pilot study design, neurostimulation devices and perfusion 
measurement instrumentation that are currently available will be discussed in detail. 
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CHAPTER 2 – NEUROSTIMULATION TECHNIQUES 
2.1 Transcutaneous Electrical Nerve Stimulation  
 Transcutaneous electrical nerve stimulation (TENS) is a noninvasive 
neurostimulation technique that uses a battery-operated unit to send electrical impulses 
through the skin via attached electrodes. The intensity, duration, frequency, and pulse 
width can all be adjusted on the TENS unit. A dual channel system with four electrodes is 
commonly used to stimulate different regions (Figure 2.1).  
 
Figure 2.1: A dual-channel TENS unit consisting of four electrodes positioned over 
different regions of the body for treating peripheral pain [74] 
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The use of TENS requires a prescription from a physician for the treatment of 
symptomatic pain and management of chronic pain; the indications also include 
postoperative and posttraumatic pain. The contraindications include undiagnosed pain, 
patients with implanted electronic devices such as pacemakers, patients who are currently 
pregnant, and patients who have a history of epilepsy [75]. Typical nerves that are 
stimulated with TENS include the ulnar, median, radial, tibial, and peroneal nerves, 
which may be stimulated directly by applying the electrodes over the desired nerve or 
indirectly by applying the electrodes on the back over a specific dermatome that 
innervates the desired region. TENS may also be combined with another 
neurostimulation technique such as spinal cord stimulation [76].  
 The mechanism of action for TENS in the mitigation of pain involves both the 
peripheral nervous system (PNS) and central nervous system (CNS), as discussed in 
Section 1.2. In addition to the gate control theory (Figure 1.8), low (< 10 Hz) frequency 
TENS is associated with activation of µ-opioid receptors while high (> 50 Hz) frequency 
TENS is associated with activation of δ-opioid receptors in the spinal cord and rostral 
ventromedial medulla. Furthermore, the fiber type that is activated by TENS depends on 
the level of intensity applied, i.e. sensory intensity up to and including motor threshold 
activates the Aβ-fibers, while intensities twice above motor threshold activate Aδ-fibers, 
which can also cause analgesia by activating descending inhibitory pathways, specifically 
the PAG and RVM [69, 77-79]. These relative levels of intensity and the associated fibers 
that they activate are true for the other neurostimulation techniques that will be discussed. 
Sensory intensity is defined as the perception of the electrical impulses without muscle 
contraction, while intensity at motor threshold, i.e. motor intensity, elicits muscle 
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contraction without painful sensation. If high frequency TENS is used, this is usually 
accompanied by sensory intensity, whereas low frequency TENS will usually be 
accompanied by motor intensity [69].  
A summary of various studies involving TENS and its effects on the 
cardiovascular system are shown in Table A.1 of Appendix A. All studies were 
conducted on human subjects, most of them healthy. In most cases, the intensity was 
adjusted to sensory intensity with an average pulse width of 200 µs, frequency of 100 Hz, 
and treatment duration of 15 minutes. The electrodes were applied either directly over the 
ischemic area, e.g. forearm or chest, or on the specific dermatomes that innervate the 
ischemic area, e.g. C2 – C3. Reductions in MAP and cutaneous vascular resistance 
(CVR) as well as increases in cutaneous blood flow (CBF) occurred in many of these 
studies [33, 63, 66, 67, 80, 81].  
A possible mechanism of action for these hemodynamic changes may be that 
TENS inhibits the sympathetic nervous system (SNS), possibly through a reflex response. 
It may also be causing local vasodilation through release of endogenous vasodilators 
from DRG neurons, such as substance P, which binds to NK-1 receptors located 
throughout the central and peripheral nervous systems, or calcitonin gene-related peptide 
(CGRP), which binds to CGRP-1 receptors on the endothelium [82, 83], and/or 
decreasing arterial levels of norepinephrine/epinephrine [36]. The last study by 
Indergand, et. al. stands in contrast to the rest of the studies, as no changes in MAP, 
CVR, or CBF were found with application of TENS using similar parameters to the other 
studies. This contradiction is not unique for studies investigating the use of 
neurostimulation devices and their effects on hemodynamics; SCS, EA, and IFC also 
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produce varying results [35, 84-86], making it difficult to establish whether 
neurostimulation induces beneficial hemodynamic changes.  
2.2 Spinal Cord Stimulation 
 Spinal cord stimulation (SCS) was first used in 1967 by Dr. Norman Shealy and 
colleagues. It involves the implantation of electrodes in the epidural space which 
transmits current across the spinal cord or near the nerve roots. The electrode-containing 
leads are connected to an implanted pulse generator (IPG) or a radio-frequency (RF) unit, 
both of which serve as pulse generators that drive the current. The IPG or RF unit is 
usually implanted in the lower abdominal area or in the gluteal region, but can also be 
implanted between the shoulder blades for cervical or occipital generators [38]. The IPG 
has its own battery, so replacement is eventually required, even if it is rechargeable. The 
RF unit has an external battery that can be easily replaced. It consists of an antenna 
attached to the patient’s skin that wirelessly communicates with the implanted receiver. 
An RF unit is usually preferable in cases where the patient will require high power 
settings for their pain treatment, although newer rechargeable IPGs are quickly replacing 
their use [87, 88]. A programmer allows adjustment of the stimulation settings by the user 
or surgeon. The leads may be cylindrical or paddle type. In both cases, a trial is 
implemented to ensure that the electrically- induced paresthesia completely masks the 
painful region, which is referred to as concordant paresthesia [89]. A successful trial is 
one that provides at least a 50% reduction in pain, which can be assessed using the Visual 
Analog Scale for pain intensity [90, 91]. Current steering is a newer advancement in SCS 
lead technology, in which multiple independent current sources and sinks are used, and 
the current from either the source or sink is gradually decreased from one electrode and 
increased to another or vice versa; this allows for more efficient programming, such that 
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the area of pain coverage is optimized [87, 92]. A straight percutaneous trial is used for 
the insertion of cylindrical leads, which involves maneuvering the lead into the posterior 
paramedian epidural space up to the painful location and anchoring the lead to the 
interspinal ligaments with nonabsorbable sutures. After the trial period, the trial lead is 
replaced by a new lead, which is connected to the IPG. Insertion of paddle-type leads 
requires a permanent lead trial, which is a more invasive and risky procedure. A 
laminotomy is performed, which partially removes the lamina, so that the electrodes can 
be slipped into the epidural space. From there, a percutaneous extension piece is tunneled 
from the site of incision out through the skin where it is secured with sutures. If the trial 
is successful, the incision is re-opened and this extension piece is cut, and new extensions 
are used to connect the leads to the IPG. [38, 87]. The advantage of using paddle-type 
leads is that there is less risk of lead migration, where lead movement causes a loss of 
paresthesia over the painful region and possible stimulation of other regions, which is a 
serious complication associated with spinal cord stimulator implantation and requires 
revision surgery [93]. The basic steps involved with the implantation procedure are 
shown in Figure 2.2. 
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Figure 2.2: Overview of SCS procedure showing where the electrodes and IPG are 
placed as well as the basic functions of each component [94] 
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 Before deciding on SCS as a pain management therapy, the McGill Pain 
Questionnaire, Roland Morris Questionnaire, or other methods are used for psychological 
screening and pain evaluation. This is to ensure that the patient will actually be amenable 
to the therapy, that any prior psychiatric disorders do not interfere with the therapy, and 
that the therapy does not aggravate any symptoms of the disorder [87, 95]. Further patient 
selection criteria for SCS include unresponsiveness to standard treatments and 
inadvisable remedial surgery [95]. In the U.S., the most common indication for use is for 
failed back surgery syndrome (FBSS), while peripheral ischemia is the most common 
indication in Europe [87, 93]. Contraindications include failed trials with SCS, bleeding 
disorders, pacemakers or defibrillators, pregnancy, and severe systemic or local 
infections [87].  
A summary of various studies involving SCS and its effects on the cardiovascular 
system are shown in Table A.2 of Appendix A. These studies were conducted both on 
rats and patients with PAOD. The pulse width was constant in all studies at 200 µs while 
the frequency was either adjusted to a high setting (~100 Hz) or medium setting (~50 
Hz). The treatment duration for rats was significantly shorter (on the order of minutes) 
compared to humans (on the order of months). This disparity in treatment duration is 
based on acute study design for animals versus permanent implantation in humans. One 
advantage to a longer treatment duration is that it allows for analysis of long-term safety 
and effectiveness with SCS that cannot as readily be assessed with other neurostimulation 
techniques. The electrode array was inserted into the epidural space using the straight 
percutaneous method over specific vertebral levels, depending on which limbs were 
affected, e.g. the electrodes were placed at the T-10 vertebral level if ischemia was 
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present in the legs [32]. Reductions in MAP and vascular resistance as well as increases 
in blood flow were observed in these studies [32, 37, 96, 97]. 
 A possible mechanism of action for these hemodynamic changes may be that 
SCS causes antidromic activation, i.e. conduction in the opposite direction of both 
cutaneous and muscle afferents, which releases vasodilators, such as calcitonin gene-
related peptide (CGRP), from the dorsal roots (Figure 2.3) [96, 97]. Through a very 
similar pathway, prostaglandins, specifically PGE2, may be released from the 
endothelium causing a reduction in sympathetic tone by inhibiting norepinephrine release 
from sympathetic nerve terminals [32]. In fact, when indomethacin, a prostaglandin 
synthesis inhibitor, was intravenously injected into cats experiencing SCS, vasodilation 
was significantly reduced, and in some cases, abolished [98]. 
 
 
 
 
 
 
Figure 2.3: Possible mechanism of action for SCS-induced hemodynamic changes. High 
intensity electrical stimulation in the epidural space activates both Aδ-fibers and C-fibers 
in the dorsal root ganglion (DRG), both of which activate extracellular signal-regulated 
kinase (ERK) and protein kinase B (AKT) that cause activation of the transient receptor 
potential vanilloid receptor-1 (TRPV-1) on these neurons. Activation of TRPV-1 releases 
CGRP that causes systemic effects such as release of nitric oxide (NO) from ECs and 
SMC relaxation, leading to increased blood flow and decreased vascular resistance [99] 
2.3 Electroacupuncture 
 Traditional acupuncture has been used for over 3000 years. This ancient Chinese 
therapy is based on the premise of restoring a blockage in “ch’i” through a careful 
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balancing of “yin and yang”. This is accomplished through the application of needles at 
specific acupuncture points (acupoints) along the body. Although largely discredited at 
first for its metaphysical explanations, such as the idea of manipulating the life energy 
“ch’i” that flows through “meridians”, i.e. channel networks within the body, by 
stimulating acupoints that run along these meridians, it has become a very popular form 
of therapy for chronic pain in the past several decades [100]. In 1975, it was found that 
by adding electricity to the needles, the pain modulation was 100% more effective over 
traditional needles [101]. Thus, electroacupuncture (EA) was born.  
 Both traditional acupuncture and EA have now found widespread use in the U.S. 
In a National Health Statistics Report, the number of Americans actively using 
electroacupuncture as an adjunct treatment for chronic pain was estimated at 3 million 
[102]. The rise in popularity for EA mirrors the rise in alternative medicine use in general 
over more conventional forms of medicine, part of this owing to its ease of use. Small 
alligator-clip electrodes are attached to each needle, each with an associated lead that 
plugs into the electrotherapy device. The downside of EA and traditional acupuncture is 
that a licensed practitioner must perform the procedure each time. However, there are 
newer forms of EA that do not utilize needles and instead use adhesive electrodes very 
similar to those used for TENS, which then allows the user to perform the procedure 
themselves. Around 30 minutes of continuous stimulation is usually recommended [103]. 
An example of a typical EA configuration using needles is shown in Figure 2.4.  
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Figure 2.4: Set-up of an EA unit on a patient, consisting of electrodes with leads inserted 
into a programmable stimulator [104]  
 Unfortunately, there is not a substantial body of evidence to support the efficacy 
of EA as a pain management therapy and the mechanisms of action are still poorly 
understood [105-108]. For this reason, EA is not commonly prescribed by physicians for 
pain treatment. Nevertheless, it is increasingly being used by the general public, and more 
clinical trials are underway to investigate both the mechanisms and potential treatments 
for this neurostimulation technique; in fact, there are currently 36 clinical trials involving 
EA that are actively recruiting according to the National Institutes of Health (NIH) [109]. 
Furthermore, when EA is combined with conventional medication, such as prednisone, 
the clinical effectiveness is even greater in reducing pain compared to medication alone 
[109-111]. Although specific indications for use have not been established yet, EA is 
generally used as an analgesic for muscle spasms, neurological disorders, chronic pain, 
injuries, and paralysis [107]. The main contraindications include patients with a history of 
seizures, heart disease, stroke, or epilepsy, as well as patients with implantable electrical 
devices such as pacemakers [103].  
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A summary of various studies involving EA and its effects on the cardiovascular 
system are shown in Table A.3 of Appendix A. Very few of these studies involved 
humans; most used rats and dogs. Very high intensities (~5x above sensory intensity) 
were used in all these studies, which appears to be necessary to alter blood flow. Wider 
pulse widths (> 250 µs) and lower frequencies (< 20 Hz) were used compared to the 
TENS and SCS studies. The electrodes were applied at acupoints specific to the ischemic 
area. The effect of electrode placement was commonly investigated in these studies, as 
stimulation of different acupoints may cause very different changes within the 
cardiovascular system, e.g. stimulation of the hand caused decreased BP and blood flow 
while stimulation of the tibial and saphenous nerves caused increased BP and blood flow 
[112, 113], although these results may also be attributable to differences in animal and 
human hemodynamics.  
A possible mechanism of action for these hemodynamic changes may be that EA 
decreases or increases sympathetic tone depending on where stimulation is applied. A 
decrease in sympathetic tone may result from a similar pathway as presented in Figure 
2.3, in which vasodilation occurs from the release of CGRP [68, 114]. Changes in activity 
of different brain regions in response to EA may also be responsible for the decrease in 
SNS activity, e.g. modulation of RVM neurons responsible for the maintenance of 
arterial BP, increased expression of nitric oxide synthase in the hypothalamus, or 
activation of nucleus ambiguus (NAmb) neurons responsible for the regulation of 
autonomic functions [115] In contrast, an increase in sympathetic tone may result from a 
reduction in prostaglandin release [116, 117]; it may also be attributed to increases in 
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muscle sympathetic nerve activity (MSNA), which may possibly occur from a 
modulatory effect on PAG and arcuate neurons that control BP [115, 118]. 
2.4 Interferential Current 
 Interferential Current (IFC) stimulation is a noninvasive neurostimulation 
technique that is very similar to TENS in terms of its application and use. It utilizes the 
same type of adhesive skin electrodes connected via leads to a stimulator unit. The main 
difference with IFC, as compared to TENS, is the frequency used. Alternating-current 
(AC) sine waves or square waves at two different carrier frequencies superimpose to 
produce an interference, i.e. interferential current, otherwise known as an alternating 
modulation frequency (AMF). Typically, one current is held at 4000 Hz while the other is 
held at 4100 Hz to produce an AMF of 100 Hz [75]. One advantage of this approach is 
that IFC can penetrate into deeper tissues because skin impedance decreases with 
increasing frequency, which is important for stimulating both cutaneous and muscle 
afferents [75, 119]. The duration of stimulation for IFC is usually around 30 minutes, 
similar to that of other neurostimulation techniques [119]. 
 Although more commonly used in other countries, IFC is increasingly used in the 
U.S. because of its reported effectiveness and ease of use [71, 120, 121]. However, its use 
normally requires oversight by a trained practitioner to ensure that modulation of the 
currents is properly performed. An example of how this modulation is accomplished 
clinically is shown in Figure 2.5.  
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Figure 2.5: Diagram showing how a dual-channel IFC unit can be applied to the skin 
surface to produce an AMF and potentially cause pain relief within deep tissue [119] 
Most IFC devices tend to be more expensive and less portable than TENS devices, 
making their widespread use further limited [119]. More portable units have been 
developed recently, including multi-functional units capable of both IFC and TENS, 
making this intervention more cost-effective [75]. IFC is indicated for use in chronic 
pain, post-traumatic pain, and post-surgical pain. However, the clinical use of IFC over 
TENS has come into question, as some studies have shown that it is no more effective at 
relieving pain than TENS [122, 123]. The contraindications for IFC include undiagnosed 
pain, infections or inflammation in the stimulation region, patients with implanted 
pacemakers or defibrillators, and patients who have a history of epilepsy [75]. 
A summary of various studies involving IFC and its effects on the cardiovascular 
system are shown in Table A.4 of Appendix A. All these studies were conducted on 
healthy human subjects. In all cases, the intensity level was adjusted to sensory intensity 
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with an average pulse width of 160 µs, frequency of 100 Hz, and treatment duration of 20 
minutes. The electrodes were applied on specific dermatomes e.g. C7 and T4, the thigh, 
or the forearm. Reductions in MAP, CVR, and ischemic pain, as well as increases in CBF 
were witnessed in these studies [124-126].  
A possible mechanism of action for these hemodynamic changes may be that IFC 
inhibits SNS activity and causes local vasodilation based on very similar mechanisms as 
discussed in Section 2.1 involving TENS. Whether the inhibition in SNS activity and 
local vasodilation is more pronounced with IFC compared to TENS is still to be 
determined, but it seems likely that this would be the case, since IFC stimulates deeper 
muscle afferents in addition to cutaneous afferents [119]. This idea will be further 
explored in Chapters 4 and 5. 
In all these neurostimulation studies, perfusion was measured in a variety of ways 
including laser Doppler flowmetry, laser speckle contrast analysis, venous occlusion 
plethysmography, and photoplethysmography, among others. The accurate interpretation 
of perfusion is crucial to fully understanding the mechanisms underlying hemodynamic 
responses to neurostimulation. This interpretation can be biased by a number of factors, 
such as motion artifact caused by movement of the subject or the connecting cables, 
calibration method (every manufacturer calibrates the equipment differently), 
temperature fluctuations, and inherent differences in the way each system measures 
perfusion. For example, laser speckle contrast analysis uses spatial averaging when 
scanning over a tissue region, which leads to a loss of resolution and an underestimation 
of the actual perfusion within this region [127]. Commonly used perfusion measurement 
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systems will be discussed in Chapter 3, including each system’s inherent advantages and 
disadvantages.  
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CHAPTER 3 – PERFUSION MEASUREMENT INSTRUMENTATION 
3.1 Justification for Non-invasive Measurements of Perfusion 
 Before discussing the theory and practical use of these perfusion measurement 
systems, the reasoning for why noninvasive perfusion systems are capable of providing 
accurate measures of both cutaneous and muscle blood flow will be explained. During a 
resting state, partition of blood flow to the muscle and skin is nearly equivalent with a 
slightly higher percentage of blood flow in the muscle. In a diseased state, such as CHF, 
blood flow in both vascular beds is reduced compared to healthy subjects. During 
exercise, both cutaneous and muscle blood flow decrease in non-active vascular beds and 
increase in active vascular beds [128]. A change in skin temperature can also be 
correlated with changes in cutaneous blood flow, since heat is a by-product of cellular 
metabolism [129]. Based on these correlations between cutaneous and muscle blood 
flow, measurements of cutaneous blood flow using noninvasive methods, such as laser 
Doppler flowmetry (LDF), can be used to estimate muscle blood flow, and perfusion in 
other vascular beds such as coronary and renal. This has important applications in the 
diagnosis and treatment of cardiovascular diseases. For example, cutaneous 
microangiopathy is associated with diabetic retinopathy and renal microvascular disease, 
in which cutaneous blood flow decreases as a function of the severity of the disease 
[130]. Cutaneous microcirculatory dysfunction has also been implicated in CAD patients 
who exhibit impaired post-ischemic capillary perfusion, i.e. reactive hyperemia, but 
normal perfusion during resting conditions [131]. This is in accordance with PAOD 
patients who also exhibit impaired reactive hyperemia [132]. Most importantly, 
noninvasive measurements of perfusion can provide relative measures of ischemia and 
reperfusion, which correlate well with more traditional, invasive measurements of 
40 
 
perfusion, such as the hydrogen clearance, Xenon clearance, fluorescent dye studies, and 
photoplethysmography [133, 134]. For the pre-pilot work (Chapter 5) and eventual pilot 
study (Chapter 4), LDF was chosen to measure cutaneous blood flow, because of its high 
sensitivity to local microcirculatory changes, ability for continuous, real-time 
measurements, noninvasiveness, and ease of use. 
3.2 Laser Doppler Flowmetry 
 Laser Doppler flowmetry (LDF) was developed in 1984, when Allan Holloway 
unveiled the first noninvasive blood perfusion monitoring system capable of continuous, 
real-time measurements. Utilizing a Helium-Neon laser source and an optical fiber, light 
is transmitted at 632.8 nm from the system to the skin. Depending on the particular probe 
configuration, a penetration depth of 1 – 1.5 mm is possible. The light that is transmitted 
to the skin is reflected back to a photodetector through “receiving” optical fibers. For 
nonmoving components within the skin, this light is reflected back at the same frequency 
as the incident source. For moving components, such as red blood cells (RBCs), the light 
is Doppler shifted or scattered, such that the frequency changes when it hits the 
photodetector. This frequency shift or beat frequency is directly proportional to the 
velocity of the RBCs or other moving components, i.e. higher velocities cause greater 
frequency shifts compared to the incident frequency [127, 135]. A diagram of this 
phenomenon is shown in Figure 3.1. The measured output of LDF systems is in flux, 
measured in perfusion units (PU), which is calculated as such: 
𝐹𝑙𝑢𝑥 = 𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑅𝐵𝐶𝑠 𝑚𝑜𝑣𝑖𝑛𝑔 𝑖𝑛 𝑡ℎ𝑒 𝑡𝑖𝑠𝑠𝑢𝑒 𝑠𝑎𝑚𝑝𝑙𝑖𝑛𝑔 𝑣𝑜𝑙𝑢𝑚𝑒 × 𝑅𝐵𝐶 𝑚𝑒𝑎𝑛 𝑣𝑒𝑙𝑜𝑐𝑖𝑡𝑦  
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Figure 3.1: Light from the incident source impinges on both non-moving components 
within the tissue and from RBCs, which is then reflected back to a photodetector and 
processed [136] 
 Within the practice of LDF, laser Doppler perfusion monitoring (LDPM) and 
laser Doppler perfusion imaging (LDPI) systems are used. LDPM systems measure 
perfusion within a very small region or point, usually the equivalent of 1 mm3 in terms of 
tissue volume, which may vary based on site of observation and concentration of RBCs at 
the time of measurement [136].  LDPI systems measure perfusion in much larger areas, 
upwards of 1000 cm2 [137]. The larger spatial field of view is accomplished via a 
complementary metal-oxide semiconductor (CMOS) camera (Figure 3.2). In this case, 
the reflected or backscattered light from the tissue is focused onto a detector array within 
the camera. Each pixel in the array is used to calculate a perfusion value for that specific 
pixel dimension within the tissue. With these CMOS cameras, the entire image is 
illuminated and acquired simultaneously. Average perfusion values can then be 
calculated for specific regions within the field of view using specially designed software. 
This is a distinct advantage over earlier versions of the LDPI systems, which scanned the 
area point by point, making the whole process take significantly longer [127]. Both 
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LDPM and LDPI systems have been used in a variety of applications including burn and 
wound assessment, quantification of microcirculatory disorders, amputation level 
determination, and dentistry, among others [127, 136, 137]. LDPM tends to be more 
useful in quantifying temporal changes within cutaneous vasculature, such as during 
vascular occlusion tests or in response to electrical stimulation [138]. LDPI serves better 
as a clinical diagnostic tool, e.g. ulcer or diabetic microangiopathy assessments [127]. An 
example of a blood perfusion map using LDPI in the case of induced ischemia is shown 
in Figure 3.3.  
 
Figure 3.2: Equipment set-up for a typical LDPI system [139] 
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Figure 3.3: Blood perfusion map using LDPI on the hand; participant subjected to a 
vascular occlusion test to simulate ischemia; perfusion scale bar shown on right [137] 
 Although LDF is being used more often in research and clinical settings, as 
indicated in Figure 3.4, there are still a number of drawbacks that limit its widespread 
use and applicability. For one, there is significant inter-individual variability in the 
measurements obtained, because of differing hematocrit levels and physiological states of 
each subject, as well as variability introduced by several environmental factors including 
ambient temperature and humidity. Absolute calibration of the LDF system is difficult 
and each manufacturer tends to go about it in a different way. The variability in both 
calibration and among individuals make standardization and repeatability problematic 
[127]. Probe placement with LDPM systems is subjective, considering that the volume of 
tissue that is measured is very small and most tissue types exhibit heterogenous blood 
flow, even within the same relative location. This usually prevents comparison of results 
to other studies [140]. However, microvascular reactivity, such as in the case of occlusion 
tests, can be compared readily to other studies by calculating a percentage change from 
an initial baseline value [141]. Even with newer CMOS cameras, LDPI systems aren’t 
fast enough to capture the frequency content of the Doppler signal in its entirety. A 
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normal Doppler power spectrum has frequency components up to 15 kHz, so the 
sampling frequency of the LDPI system must be at least double that [127]; even with 
some of the newest systems on the market today, this sampling frequency is still not yet 
achievable [137, 142]. This lower sampling frequency tends to lead to underestimation of 
the actual perfusion values [127]. In more recent years, there have been concerted efforts 
to create internationally standardized protocols for data recording and for various 
diagnoses, making the LDF method a more useful and reliable tool for monitoring the 
microcirculation [143].  
 
Figure 3.4: The number of publications utilizing the LDF method, either LDPM or LDPI, 
from 1980 through 2006 [144] 
3.3 Laser Speckle Contrast Analysis  
Laser speckle contrast analysis (LASCA), otherwise known as laser speckle 
contrast imaging (LSCI) or simply laser speckle imaging (LSI), utilizes very similar 
methodology as LDF in measuring microcirculation. “Laser speckle” is an interference 
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pattern produced from light beams of the same frequency. This is in contrast to LDF 
where the superimposed waves have different frequencies. However, in both cases, 
identical equations are used to correlate the random fluctuations caused by changes in 
optical path lengths of the light beams to the velocity distribution of the moving 
components, i.e. RBCs within a given tissue. If the object is static, no change in optical 
path length will occur, and thus the speckle pattern will remain stationary. To scan a 
given area, a set-up very similar to Figure 3.2 for an LDPI system is typically used. A 
number of parameters can be manipulated with the resulting contrast map including the 
exposure time, number of pixels, scaling, and color coding. The number of pixels is 
important, because with too few pixels, proper statistical analysis cannot be performed to 
analyze the image, and with too many pixels, the spatial resolution is significantly 
diminished [127].  
LASCA was originally only used for measuring perfusion in the skin, but has now 
become extremely important for monitoring cerebral blood flow [127, 145-147]. The 
increase in use for LASCA is partially because it has quicker response times than LDPI, 
which helps to improve patient comfort since they must remain perfectly still during the 
scan [148]. The LASCA method is capable of near real-time imaging (capture and 
processing takes less than a second on average), which is important when evaluating 
mechanical or pharmacological interventions on the microcirculation. However, LASCA, 
unlike LDF methods, does not measure the frequency spectrum; it only measures the 
velocity distribution. Therefore, only an average velocity of RBCs can be obtained rather 
than flux, i.e. perfusion. Furthermore, the velocity distribution within a given tissue must 
be assumed to use the equations associated with this technique [149]. The most 
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significant disadvantage is the loss of resolution caused by the spatial averaging used in 
the analysis [127]. However, more recent developments in LASCA technology and the 
algorithms used have ameliorated many of these disadvantages and made this technique 
more comparable to LDPI [127, 140, 148].  
3.4 High Frequency Ultrasound 
 Ultrasound has been around since the late 1940s, when it was first used in sonar 
technology during World War II. Then, in 1955, Shigeo Satomura and Yasuhara Nimura 
developed the first Doppler ultrasound device, specifically for monitoring blood flow. It 
is now commonly utilized as a diagnostic imaging modality in medicine [150]. 
Ultrasound, as the term implies, is a sound wave that can be affected by properties of the 
medium such as density, as well as environmental factors such as temperature. However, 
it has a much higher frequency (> 20 kHz) than normal sound waves, but still behaves 
like a wave in that it transmits energy from one source to another. In ultrasound imaging 
systems, ultrasonic waves from a transducer propagate through a tissue and interact with 
mechanical discontinuities, e.g. planar interfaces between the skull and brain or between 
fat and liver. An echo is created from this interaction, which is a reflection or scattering 
of the original ultrasonic wave; ultrasonic images are then formed from these echoes 
[127, 150]. The acoustic impedance of the ultrasound system is the primary factor that 
determines the amplitude of a given echo. As an example, blood vessels are mainly 
composed of connective tissue, and connective tissue exhibits impedance; thus, blood 
vessels tend to be more “echogenic”, i.e. reflect more of the sound waves because of their 
higher acoustic impedance [150]. In terms of measuring blood flow, the Doppler effect is 
utilized in the exact same manner as with LDF. Moving components, such as RBCs, 
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scatter the ultrasonic wave, which leads to a shift in frequency of the reflected waves, and 
this frequency shift is directly proportional to the velocity of the moving components.  
 Although ultrasound has been used to monitor blood flow for decades, it wasn’t 
until the early 2000s that the microcirculation could be properly imaged. The reason for 
this was the limitation in imaging frequency and resolution. Before this time, maximum 
imaging frequencies were between 12 – 15 MHz with a resolution of about 300 µm. With 
the development of micro-ultrasound, imaging frequencies are now in the 15 – 80 MHz 
range with resolutions in the 40 – 200 µm range [127]. The output of these systems can 
be displayed in a number of ways including pulsed Doppler, color Doppler, and power 
Doppler. Pulsed Doppler measures blood velocity with respect to time at one point in 
space, so it outputs the hemodynamics of that location. If vessel cross-sectional area can 
be determined, then flow rate in milliliters per minute can be calculated. Color Doppler 
presents a cover overlay of mean RBC velocity on top of a grayscale image of the 
anatomy, and can be used to distinguish arterial versus venous blood flow (Figure 3.5). 
However, it is only capable of providing relative flow velocities, unlike pulsed Doppler. 
Power Doppler computes the integral of the Doppler power spectrum, which is a 
representation of relative blood volume, assuming constant hematocrit. Therefore, it can 
provide a morphological image of the microvasculature in the region of interest (ROI). 
Vessels that are smaller than 50 µm cannot usually be detected by power Doppler, and 
this modality is more prone to motion artifact than the others [151].  
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Figure 3.5: Color Doppler image of the brain cortex showing blood flow away from the 
transducer in blue and blood flow toward the transducer in red [151] 
3.5 Other Instrumentation 
 A full review of current microcirculation monitoring techniques is beyond the 
scope of this work and a more comprehensive and detailed review can be found in 
Microcirculation Imaging by M.J. Leahy [127]. A brief description of some of these 
other imaging modalities will be discussed here. These include photoplethysmography 
(PPG), nuclear magnetic resonance imaging (NMRI), and micro-positron emission 
tomography (micro-PET).  
 PPG has been used to measure skin blood flow since the late 1940s. It utilizes 
electromagnetic radiation, which is transmitted from an infrared light-emitting diode 
(LED) source to the skin. The backscatter is measured in terms of hemoglobin absorption 
by a phototransistor, which indicates the relative volume of blood in the ROI. After signal 
processing, the output is displayed on a chart recorder. The measurement depth is around 
1 – 1.5 mm for most probes, which are noninvasive like the LDPM probes. PPG is used 
in the assessment of skin ulcers and flap viability, in the evaluation of PAOD and CVD, 
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and in measuring the pharmacodynamic response of various drugs on the circulation 
[135].  
 NMRI is capable of quantifying blood flow within the entire size range of the 
vasculature, i.e. large diameter arteries and small diameter capillaries. This is 
accomplished either through arterial spin labeling (ASL) or dynamic susceptibility 
contrast (DSC). ASL uses magnetically-‘labeled’ water protons that function as a tracer, 
which is similar to other imaging modalities such as single-photon emission computed 
tomography (SPECT), PET, and CT, except that there is no injection of a contrast agent; 
it instead labels the “blood magnetization”. DSC uses an injection of a contrast agent 
called Gadolinium (Gd) encapsulated in a chelate molecule for dynamic imaging. 
Although DSC is a more clinically viable option in terms of high signal-to-noise ratios 
and simple acquisition procedures, ASL is completely non-invasive, can be operator-
independent, and is intrinsically more quantitative; hence its popularity in research and 
the clinical setting is increasing [152]. In ASL, blood flow causes a shift in magnetization 
that is displayed on the resulting image, which is subtracted from a “control” image 
where there is no magnetization [127]. There are numerous ways of labeling this 
magnetization, most commonly continuous or pulsed ASL is used, as well as numerous 
ways of acquiring the image signal and quantifying the blood flow. However, recently the 
ASL Network was established to assimilate the many different procedures and theories 
used in this technique in the hopes of increasing its clinical utility [152].  
 PET systems have been in use since the 1960s and have served as a powerful 
clinical diagnostic tool in terms of noninvasively studying human physiology and 
biochemistry. Starting in the 1990s, PET systems were scaled down to produce 
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resolutions of around 2 mm, which is when the term micro-PET became popular. Micro-
PET uses a radioactive substance that decays by positron emission when it collides with 
an electron.  This annihilation causes high-energy photons to be emitted, which are 
collected by the micro-PET detectors. By collecting a multitude of photon pairs, a 
topographic image is created. This technique has the advantages of being very sensitive, 
having high signal-to-noise ratios, and having the capability of imaging any type of target 
from metabolic substrates to nanoparticles. Thus, absolute measurements of blood flow 
are possible [127]. However, it is still limited in terms of its spatial resolution because of 
the finite distance that the positron can travel in any given tissue before collision. In 
addition, many of the radioisotopes used in perfusion monitoring have short half-lives, 
although newer agents such as [11C]DMDPA have helped mitigate this pitfall [153]. The 
combination of micro-PET with micro-computed tomography (micro-CT) scanners has 
vastly improved the spatial resolution as well; this type of dual modality imaging system 
is shown in Figure 3.6.   
 
Figure 3.6: Siemens Inveon Micro-CT/PET system capable of ultra-high resolutions 
down to 15 µm [154] 
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CHAPTER 4 – CLINICAL PILOT STUDY DESIGN 
4.1 Justification for the Use of TENS 
 The use of TENS for the pilot study was chosen because of its low cost, well-
established parameters for safe and effective use, and its favorable impact on 
hemodynamics and pain reduction in humans. Since this was a pilot study in healthy 
subjects, SCS was not chosen due to its invasiveness. EA and TENS have similar effects 
on cutaneous blood flow and skin temperature in the hand [65]. However, EA use is 
limited by the need for a licensed acupuncturist to properly place the electrodes at the 
correct acupoints. In addition, most of the research involving EA has been conducted on 
animals, and with mixed results [64, 68, 113, 155]. For the pilot study, we  compared our 
results to other healthy, human subject studies using similar protocols with TENS. There 
is no difference between TENS and IFC in terms of treating chronic back pain, but both 
are still more effective than no treatment, i.e. both treatments caused reductions in the 
Visual Analog Scale (VAS) and Roland-Morris Disability Questionnaire (RMDQ) with 
regards to pain intensity, consumption of pain medications, and disability [70]. Even with 
ischemia- induced pain, both techniques are nearly equivalent in their analgesic effects 
when comparing reductions in pain intensity using the VAS and McGill Pain 
Questionnaire (MPQ) [119]. As far as we know, there have been no direct comparisons of 
the effect of IFC and TENS on the cardiovascular system, although separate studies of 
IFC and TENS using almost identical protocols have been conducted, but the authors 
only mentioned that similar results were obtained, i.e. reductions in MAP and calf 
vascular resistance with simultaneous increases in calf blood flow [81, 126]. One of the 
goals of this study was to investigate these two neurostimulation techniques and 
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determine which elicited greater hemodynamic changes, which will be discussed in more 
detail in Chapter 5.  
4.2 Mechanism of Action of TENS on Hemodynamics 
 The gate control theory has been used for decades to explain how 
neurostimulation effectively mitigates pain, but it has not been used to explain the 
changes that are witnessed within the cardiovascular system, i.e. increased blood flow, 
decreased blood pressure (BP), and decreased vascular resistance. Specifically, TENS 
seems to modulate the gate control system by stimulating large diameter, Aβ-fibers and 
Group I – II muscle afferents, causing an increased inhibitory effect of GABA on NS and 
WDR neurons. This effectively reduces the transmission of pain signals carried by small 
diameter, C-fibers and Group III – IV muscle afferents to the dorsal horn neurons. Thus, 
the original noxious stimulus still reaches the brain, but the painful sensation and 
response that occurs is reduced [47, 156, 157].  
Simultaneous to the reduced pain sensation, the metaboreflex may be reduced. 
Normally, the metaboreflex (muscle chemoreflex) is triggered by ischemic by-products, 
e.g. lactic acid, hydrogen ions, adenosine, prostaglandins, bradykinin, and potassium, 
with potassium being the most potent stimulator of intramuscular chemoreceptors located 
on group III – IV muscle afferents [158-161]. The metaboreflex causes an increase in 
sympathetic activity, which in turn increases cardiac output (higher HR and SV) and 
vasoconstriction in nonactive tissues [162]. At the same time, there is a blunted 
vasoconstrictive effect on active tissues (due to functional sympatholysis), leading to a 
net increase in blood flow and oxygen to these tissues [163]. Although this process is 
imperative in healthy individuals to redistribute blood flow to active tissues during 
exercise, it can actually worsen the symptoms in PAOD patients who have increased 
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reactive oxygen species (ROS) production as a result of the disease, which also stimulates 
Group IV muscle afferents, [164, 165]. This is evidenced by greater changes in MAP in 
response to exercise and more sympathetic activation, which is related to disease severity, 
i.e. the more severe the disease state, the greater the metaboreflex activation will be and 
the more sympathetic activation that will occur [165]. Thus, there is likely to be a more 
pronounced effect when TENS is used on PAOD patients compared to on healthy 
individuals. Specifically, it should reduce BP but should not affect HR substantially, 
because TENS at sensory intensity does not affect descending control mechanisms from 
the brain, and it is these central mechanisms that influence HR [156, 166]. Furthermore, 
the effect of TENS on HR has produced inconclusive results [33, 67, 81].  
The reduction in the metaboreflex, in theory, should not cause local vasodilation, 
yet in many studies, an increase in blood flow still occurs with application of TENS [33, 
36, 66, 167]. Therefore, an additional mechanism must be at work to explain this local 
vasodilatory effect. A few studies have investigated how catecholamine metabolism 
increases in response to TENS and the findings suggest that it may be inhib iting 
norepinephrine (NE) release [33, 36, 79, 168]. This inhibition of NE release may occur if 
TENS causes serotonin release. As stated in Section 2.1, high frequency (> 50 Hz) TENS 
activates δ-opioid receptors and low frequency TENS (< 10 Hz) activates µ-opioid 
receptors in the RVM and the spinal cord [69, 169]. This activation may occur through 
release of β-endorphins that selectively bind to µ-opioid receptors [170] or the release of 
enkephalins that selectively bind to δ-opioid receptors [171]. A complex presynaptic 
synergistic interaction between opioid receptors and serotonin (5-HT) receptors is 
responsible for some of the anti-nociceptive effects of electrical stimulation, possibly 
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through a decrease in GABA release in spinal interneurons, although this is not fully 
understood [172, 173]. TENS stimulates release of serotonin from the raphe nuclei into 
the spinal cord, which then activates 5-HT1, 5-HT2, and 5-HT3 receptors [174, 175]. 
Serotonin can either have a depressor effect if neurogenic vasoconstriction is present, as 
in the case of PAOD patients, or can have a pressor effect if neurogenic vasoconstriction 
is absent [176]. In the case of this depressor effect, presynaptic inhibition of NE from 
sympathetic nerve terminals occurs [177]. Normally, electrical stimulation, such as 
TENS, stimulates a vasoconstrictor response through the release of NE and ATP from 
postganglionic sympathetic neurons [178, 179]. NE activates α2 adrenergic receptors, 
which are part of a larger class of adrenergic receptors that mediate smooth muscle 
contraction, i.e. vasoconstriction. The α2 receptors exist on SMCs, sympathetic nerve 
terminals, peripheral nerve terminals of primary afferent neurons, around injured 
peripheral nerves, the dorsal horn of the spinal cord, central terminals of primary afferent 
neurons, and in the RVM, locus coeruleus, and other brain regions [180]. They are also 
the only adrenergic receptors that are associated with presynaptic inhibition, specifically 
of NE, and provide negative feedback to stimulated NE release. Depolarization-induced 
release of neurotransmitters, such as NE, from nerves is dependent on the influx of 
calcium through voltage-gated calcium channels. N-type calcium channels, which are 
coupled to α2 receptors via G-proteins, mediate calcium influx responsible for 
norepinephrine release. Serotonin decreases the calcium current through the channels. As 
a result, cytosolic levels of calcium decrease, causing inhibition of NE release from the 
sympathetic nerve terminal [177, 181]. In addition, both serotonin and activation of α2 
receptors have both been implicated in presynaptic and postsynaptic inhibition on 
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nociceptive afferents and dorsal horn neurons, resulting in analgesia [182, 183]. 
Supporting this idea, TENS-induced analgesia was reduced in mice with dysfunctional 
α2A receptors, i.e. the hypotensive action of these receptors was completely ablated, but 
not in mice with deleted α2C receptors [79]. In this same study, spinal and supraspinal 
blockade of α2 receptors in wild-type (WT) mice did not affect the antihyperalgesia of 
TENS, while blockade of α2 receptors at the site of application of TENS reduced the anti-
hyperalgesia. In addition, α2A receptors are expressed more on primary afferent neurons 
than α2C receptors, suggesting that α2A receptors are mainly responsible for the anti-
hyperalgesic effects. In this case, reductions in pain intensity, metaboreflex activation, 
and vasoconstriction could all occur through electrical stimulation of both cutaneous and 
muscle afferents.  
Although this explanation for TENS-induced vasodilation and subsequent 
increases in blood flow seems plausible, other possible receptors, paracrine factors, and 
hormones may play some role. For example, TENS-induced vasodilation may result from 
activation of β-adrenergic receptors and/or release of acetylcholine, histamine, adenosine, 
dopamine, prostaglandins or plasma kinins; however, antagonists for all of these 
vasodilators still do not reduce the vasodilatory effect of TENS [184]. TENS does 
stimulate release of nitric oxide (NO) from the pedal ganglia of blue mussels (Mytilus 
edulis) by activating opioid receptors, as opioid receptor blockade with naloxone 
prevented NO release [185]. However, NO does not seem to be responsible for the 
induced vasodilation in humans as only the analgesic effects of TENS were blocked with 
naloxone [186]. Upregulation, i.e. higher mRNA and protein levels, of CGRP, which is 
the most potent of the vasodilators in the DRG, in response to TENS is another 
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possibility for the induced vasodilation; this would further stimulate NO release from the 
endothelium and cause SMC relaxation [187, 188]. Lastly, TENS increases plasma levels 
of vasoactive intestinal polypeptide (VIP), another potent vasodilator, within the 
circulation, which the authors believed may be a secondary action attributable to a 
decrease in sympathetic activity, possibly as a result of the serotonergic pathway 
discussed earlier [189]. Evidence of TENS-induced vasodilation from any other possible 
mechanisms is currently unknown.  
Multiple mechanisms may underlie the hemodynamic changes induced by TENS, 
but it seems that a dual, synergistic mechanism is most likely responsible for these 
changes, as shown in Figure 4.1. Specifically, stimulating the Aβ cutaneous afferents and 
Group I and II muscle afferents not only closes the “gate” and reduces noxious stimulus 
transmission as previously thought, but also reduces the metaboreflex causing a decrease 
in SNS activity. In addition, TENS stimulates release of serotonin that inhibits NE release 
from sympathetic nerve terminals causing vasodilation. Through this cascade of neural 
events, the end result is a reduction in MAP with a simultaneous increase in local blood 
flow. 
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Figure 4.1: Diagram of the proposed mechanisms for TENS-induced changes on the 
cardiovascular system in PAOD patients, involving a reduction in the metaboreflex and 
presynaptic inhibition of NE from sympathetic neurons. GABA: Gamma-aminobutryic 
Acid; MAP: Mean Arterial Pressure; ROS: Reactive Oxygen Species; NE: 
Norepinephrine 
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 This proposed dual mechanism of action for application of TENS on PAOD 
patients should also apply to healthy individuals who experience induced ischemia. In 
healthy participants, i.e. no past or current history of any cardiovascular, musculoskeletal, 
or neural conditions, who experienced induced ischemia through the inflation of a blood 
pressure cuff wrapped around their forearm, MAP and vascular resistance decreased, 
while blood flow increased with TENS applied on the C7 and T4 dermatomes; this effect 
on the hemodynamics was more pronounced in younger individuals (25 ± 1.3 years of 
age) [81]. This may be surprising considering that plasma levels of NE are higher in older 
individuals [190, 191], and there is greater endothelial dysfunction and increased 
sympathetic tone [192, 193]; TENS has a greater effect when increased SNS activity is 
present, such as during isometic exercise [80]. However, the metaboreflex may be 
attenuated by age, and with reduced metaboreflex activation, the effect of TENS on SNS 
activity will also be reduced [194]. Specifically, sympathetic reactivity to isometric hand 
exercise is reduced in older individuals, meaning there is a smaller percentage increase in 
sympathetic tone with exercise as compared to young individuals [195]. This could be 
explained by the increase in oxidative fibers in skeletal muscle with age, which could 
attenuate BP and muscle sympathetic nerve activity (MSNA), i.e. less of a change with 
exercise, since glycolytic fibers exhibit a greater exercise reflex response [196]. For 
example, in mice, there is a change in muscle myosin heavy chain (MHC) isoforms from 
fast, glycolytic Type II fibers to slower, oxidative Type I fibers [197]. Since glycolytic 
muscle evokes greater metaboreflex activation than oxidative muscle [196], and if there 
is a slow transformation of muscle fibers to a more oxidative phenotype with age [195], 
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then it seems reasonable that younger individuals would experience a greater effect from 
TENS on the metaboreflex.  
 Although application of TENS may have a favorable impact on PAOD patients, 
the same may not be true of patients with other forms of cardiovascular disease, such as 
congestive heart failure (CHF) and hypertensive patients. In CHF patients, the 
metaboreflex is reduced, which is evidenced by a blunted increase in systolic blood 
pressure (SBP) and calf vascular resistance in the non-exercised limb [161]. This may be 
due to impaired left ventricular contractility, which limits cardiac output (CO). In this 
case, heart rate (HR) would increase, but stroke volume (SV) would decrease, so CO 
would not increase as much during exercise. The SV decrease is related to impaired 
contractility and increased ventricular afterload sensitivity, whereby the ventricles 
become more sensitive to pressure changes [198, 199]. An attenuation of the 
metaboreflex has also been found in hypertensive patients [200]. Thus, the effect of 
TENS may not only depend on the age of the individual, but also if that individual 
exhibits different forms of cardiovascular disease.  
4.3 Pilot Study Design 
To test the proposed mechanisms of TENS and its effects on hemodynamics, a 
pilot study will be performed after some pre-pilot work is conducted to optimize the 
study design, which will be discussed in Chapter 5; what follows is an “expected” study 
design based on a pre-approved protocol submitted to the Institutional Review Board 
(IRB) at Cal Poly.  
For this pilot study, young, healthy, college-aged students between the ages of 18 
and 24 will be recruited through department emails, fliers, and “word of mouth”. 
Volunteers will complete an informed consent document (Appendix B) and a short 
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medical history questionnaire to ensure that they do not present any of the 
contraindications for TENS and are free of any symptoms or signs of cardiovascular 
disease (Appendix C). In qualifying subjects, C7 and T4 dermatomes on the back will be 
stimulated; these dermatomes innervate the arms and hands as well as the thoracic region 
over the pectorals (Figure 4.2).  
 
Figure 4.2: Dermatomes for the various regions of the human body [201] 
TENS will be applied to these dermatomes to investigate its effectiveness in increasing 
blood flow to the limb, decreasing BP, and reducing ischemic pain, using previously 
established parameters for frequency, pulse duration, treatment duration, and intensity 
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[33, 36, 63, 67, 80, 81]. Ischemic pain in the forearm will be induced with a blood 
pressure cuff [81, 119, 192]. CBF will be measured with a non-invasive laser Doppler 
flow system (moorVMS-LDF2), BP and HR will be measured with a digital blood 
pressure monitor (Life Source UA-767 Plus), and pain intensity will be measured using 
the Numerical Pain Rating Scale (NPRS) (Appendix D).  
During one of the two treatment days, the participant will undergo the post-
exercise without circulatory occlusion (PECO-) protocol. On the other treatment day, the 
post-exercise with circulatory occlusion (PECO+) protocol will be followed. Therefore, 
all participants will undergo all treatment conditions. The order of these protocols will be 
randomized for each participant using a given code on the medical history form. The first 
15 minutes will be allocated either to the placebo condition or TENS condition, a 30-
minute break will be given, and then 15 minutes will be allocated to the other condition 
(Figure 4.3). Thus, the order of placebo and treatment conditions will also be 
randomized. During the placebo condition, subjects will have the electrodes attached to 
the upper back just as during the treatment condition, but no current will be applied from 
the TENS unit.  
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Figure 4.3: Study flow diagram for the pilot study 
We hypothesize that ischemia-induced individuals who receive TENS will exhibit 
an increase in cutaneous blood flow (CBF) and decreases in cutaneous vascular resistance 
(CVR), BP, and pain intensity compared to those who do not receive TENS. 
Furthermore, the application of TENS will cause a greater decrease in BP in ischemia-
induced individuals compared to non-ischemia-induced individuals; CVR and CBF 
responses in non-ischemia- induced individuals with TENS will be more pronounced than 
in those same individuals who do not receive TENS, i.e. CVR will decrease and CBF will 
increase. Table 4.1 shows these expected changes for the control and treatment with 
TENS groups with and without post-exercise circulatory occlusion (PECO).  
 
Eligible 
participants
Treatment 
Day 1
PECO -
Placebo
30-minute 
break
TENS
TENS
30-minute 
break
Placebo
Treatment 
Day 2
PECO +
Placebo
30-minute 
break
TENS
TENS
30-minute 
break
Placebo
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Table 4.1: Expected Outcomes for Systemic Hemodynamic Parameters and Pain Intensity 
for both Control and TENS Groups with and without PECO* 
 Control TENS 
 PECO- PECO+ PECO- PECO+ 
Heart Rate ↓ - ↓ - 
Blood Pressure ↓ - ↓ ↓↓ 
Blood Flow ↑ - ↑↑ ↑ 
Vascular Resistance ↓ - ↓↓ ↓↓ 
Pain Intensity ↓ - ↓ ↓↓ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                 
 
* PECO+ = Post-exercise with Circulatory Occlusion; PECO- = Post-exercise without Circulatory 
Occlusion; Arrows indicate change from baseline reading  
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CHAPTER 5 – PRE-PILOT WORK 
5.1 Methods 
 To optimize the future pilot study design, comparison studies between IFC and 
TENS, and two different areas of application (forearm and back) were investigated to 
determine which combinations produced the greatest hemodynamic changes. These 
studies were run over the course of three weeks on both myself and my partner in this 
project. The protocol, as described in Appendix E, was followed, except for the 
following deviations: there was only a 10 minute break in between sessions instead of 30, 
pain was assessed every 3 minutes instead of every minute, blood flow was measured in 
the left palm and anterior brachial region of the left arm instead of in the left and right 
palms, and the control condition always preceded the TENS or IFC condition instead of 
being randomized. Ischemia was induced using a manual blood pressure cuff (CVS 
Pharmacy Model #BPAG1-20CVS) wrapped around the subject’s left forearm. Isometric 
exercise was performed using a hand dynamometer. Electrical stimulation was provided 
by an InTENSity Select Combo TENS/IF/MIC/EMS Stimulator. CBF and skin 
temperature were monitored using a Moor Instruments VMS-LDF2 and VP1T/7 skin 
probes attached just distal to the elbow and wrist creases. BP and HR were assessed 
halfway through each treatment interval, i.e. baseline, occlusion, exercise, and recovery, 
using a Life Source digital blood pressure monitor (Model #UA-767 Plus) with the cuff 
wrapped around the subject’s right arm. MAP was calculated from the equation: 
𝑀𝐴𝑃 =  
2
3
𝐷𝐵𝑃 +  
1
3
𝑆𝐵𝑃 
and CVR was calculated from the equation: 
𝐶𝑉𝑅 =
𝑀𝐴𝑃
𝐶𝐵𝐹
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Respiration was monitored using a Pneumotrace II respiratory belt (ADInstruments, 
Model #MLT1132/D). If the raw breath signal exceeded ±50 mV during anytime period, 
causing motion artifact in the blood flow recordings, then the data was deleted over that 
interval. Any additional motion artifacts were also removed from the data trace. All 
measurements, besides BP, were continuously monitored using a PowerLab 26T system 
(Model #ML4856) and LabChart 7 Pro software. The output of such measurements in 
LabChart is shown in Figure 5.1, the entire experimental set-up is shown in Figure 5.2, 
the different treatment parameters, i.e. frequency, pulse width, treatment duration, and 
intensity, are shown in Table 5.1, and electrode placement for both IFC and TENS on the 
forearm and back is shown in Figure 5.3.  
 
 
 
 
 
 
 
 
 
Figure 5.1: Representative data trace showing the raw breath signal in mV, the 
respiratory rate in BPM, the grip force in N, and the blood flow measurements at the two 
different locations in PU 
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Figure 5.2: Experimental set-up for pre-pilot work A) Manual blood pressure cuff B) 
Hand dynamometer C) Digital blood pressure cuff D) Respiration belt E) LDF system F) 
PowerLab system G) Blood pressure monitor H) Stimulator I) Laptop with LabChart 
software 
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Table 5.1: Treatment Parameters for TENS and IFC Testing* 
Treatment 
Method 
Frequency (Hz) Pulse Width (µs) Treatment 
Duration (min) 
Intensity Range 
(mA) 
TENS on Back at 
High Frequency 
100 200 15 12-13 
TENS on 
Forearm at High 
Frequency 
 
100 200 15 6-8 
TENS on Back at 
Low Frequency 
4 200 15 11-14 
TENS on 
Forearm at Low 
Frequency 
 
4 200 15 6-8 
IFC on Back at 
High Frequency 
  
100 (modulated) 200 15 7-11 
IFC on Forearm 
at High 
Frequency 
  
100 (modulated) 200 15 5 
 
 
 
 
 
 
 
 
                                                                 
 
* Intensity for each subject was individually adjusted to the point just below motor threshold i.e. no visible 
muscle contraction or sensations of pain 
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Figure 5.3: Electrode placement for: IFC on the forearm (upper left), TENS on the 
forearm (upper right), IFC on the back (lower left), and TENS on the back (lower right); 
1) Channel 1 of the stimulator 2) Channel 2 of the stimulator 
The hypothesis for all the treatment conditions was that stimulation would cause 
an increase in CBF with a concomitant decrease in BP, CVR, and pain intensity. 
Furthermore, it was expected that application of IFC on the back and on the forearm 
would produce greater favorable changes in these endpoints compared to TENS, because 
of its ability to stimulate deeper tissue, i.e. more muscle afferents. It was also expected 
that high frequency TENS would be more effective than low frequency TENS, because 
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high frequency TENS produces greater inhibition of dorsal horn neuron activity than low 
frequency TENS [202]. Specifically, C-fibers are maximally suppressed at stimulation 
frequencies of 80 – 100 Hz [203]. Finally, it was expected that application of TENS on 
the back would cause similar decreases in BP as compared to application of TENS on the 
forearm, but with less of an increase in CBF (measured in the palm), since the stimulation 
current would most likely activate α2 receptors in the dorsal horn of the spinal cord more 
so than at the sympathetic nerve terminals of primary afferent neurons based on the 
electrode placement site. 
Data for the hemodynamic parameters, pain intensity, and reperfusion time were 
all analyzed in JMP Pro 11 software. Repeated measures ANOVA and Dunnett’s Test 
were used for comparisons among the different treatment conditions and comparing each 
treatment condition to the control, respectively. Statistical significance was accepted 
when P < 0.05. P-values for all hemodynamic parameters and pain intensity are shown in 
Appendix G.  
5.2 Results 
To test the proposed hypotheses for stimulation frequency and modality as well as 
electrode placement, six different treatment conditions and a control were all compared in 
terms of pain intensity, CBF in the palm and anterior brachial region, reperfusion time, 
SBP, DBP, HR, MAP, and CVR in the palm and anterior brachial region. Appendix F 
lists the averages obtained for control and treatment conditions. Figure 5.4 depicts the 
average pain intensity for baseline, exercise, occlusion and recovery, which is based on 
the Numerical Rating Scale (NRS). Figures 5.5, 5.6, and 5.8 through 5.13 depict the 
percent change for each hemodynamic parameter that was measured with regards to the 
specific treatment condition. Error bars from these figures have been removed for the 
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sake of clarity. Figure 5.7 depicts the average reperfusion time for all treatment 
conditions. 
 
Figure 5.4: Pain intensity according to the NRS during each interval for all treatment 
conditions 
Pain intensity was measured to determine if the ischemic pain induced by 
occlusion was reduced by TENS or IFC, which would indicate either a restoration of the 
oxygen supply in the ischemic region or pain modulation by activation of Aβ-fibers or a 
combination of both. TENS on the back at 4 Hz and TENS on the arm at 100 Hz 
exhibited higher pain intensity compared to control for baseline, exercise, occlusion, and 
recovery. All baseline pain intensity values were the same besides for TENS on the arm 
at 100 Hz. Pain intensity for IFC on the arm was the same as control for exercise, but 
decreased during occlusion and recovery. No statistical differences were found among the 
treatment conditions when compared with the control condition. However, TENS on the 
arm at 4 Hz and TENS on the back at 100 Hz exhibited lower pain intensity during 
exercise and occlusion, but were higher during recovery compared to control. IFC on the 
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back exhibited lower pain intensity during exercise, occlusion, and recovery compared to 
control.  
 
Figure 5.5: Blood flow in the left palm, measured as percent change from baseline 
reading, for all treatment conditions 
CBF was measured in the left palm to determine if there was a local vasodilatory 
effect from TENS or IFC, which would be exhibited as a higher percentage increase in 
CBF during exercise, occlusion, and recovery as compared to control. No statistical 
differences were found among the treatment conditions when compared with the control 
condition. However, IFC on the arm, TENS on the back at 100 Hz, and TENS on the 
back at 4 Hz all trended toward higher CBF for exercise, occlusion, and recovery 
compared to the control condition. TENS on the arm at 100 Hz trended toward lower 
CBF during exercise compared to control, but higher CBF during recovery. TENS on the 
arm at 4 Hz exhibited the opposite trend with higher CBF during exercise, but lower CBF 
during recovery. IFC on the back exhibited lower CBF during both exercise and 
recovery, but was still higher than control during occlusion.  
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Figure 5.6: Blood flow in the left anterior brachial region, measured as percent change 
from baseline reading, for all treatment conditions 
CBF was measured in the anterior brachial region to correlate the changes in 
perfusion occurring downstream of the occluded region, i.e. the palm, to changes 
upstream of this site. For example, if CBF in the left palm decreased during occlusion, 
then an increase in CBF in the left anterior brachial region would be expected, as blood 
flow is being redistributed to this ischemic region. No statistical differences were found 
among the treatment conditions when compared with the control condition. However, 
TENS on the arm at 100 Hz, IFC on the arm, TENS on the arm at 4 Hz, and TENS on the 
back at 4 Hz trended toward higher CBF values when compared to the control condition. 
IFC on the back exhibited lower CBF during exercise and occlusion, but higher CBF 
during recovery compared to control. TENS on the back at 100 Hz exhibited lower CBF 
for exercise, occlusion, and recovery compared to control.  
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Figure 5.7: Average reperfusion time, which is the time from the start of hyperemia after 
occlusion to the first instance where blood flow reaches the average baseline value, for 
all treatment conditions; *p < 0.05 compared to control  
Reperfusion time was measured to determine, not only if blood flow increases as 
a result of TENS or IFC application, but also if blood flow redistribution to the ischemic 
region is improved after occlusion. TENS on the back at 4 Hz exhibited higher 
reperfusion time compared to control. All other treatment conditions exhibited lower 
reperfusion time compared to control with IFC on the back being significantly lower. 
However, it is important to note that reperfusion time may be dependent on the 
magnitude of the perfusion change from baseline during recovery e.g. TENS on the back 
at 4 Hz exhibited higher perfusion during recovery than all other treatment conditions, 
meaning that it is possible reperfusion time was higher for this treatment condition 
because perfusion in the palm was much higher during the hyperemia stage after 
occlusion and remained higher throughout, and thus taking longer to reach the average 
baseline value. The same applies to IFC on the back, which exhibited the lowest 
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perfusion change in the palm during recovery as compared to the other treatment 
conditions, so it would take less time to reach the average baseline value.  
 
Figure 5.8: Systolic blood pressure, measured as percent change from baseline reading, 
for all treatment conditions 
SBP was measured to determine if the metaboreflex was attenuated by TENS or 
IFC, i.e. reduced SBP would indicate a possible reduction in metaboreflex activation 
during a particular phase of the protocol. No statistical differences were found among the 
treatment conditions when compared with the control condition. However, TENS on the 
back at 100 Hz trended toward a higher SBP compared to control for exercise, occlusion, 
and recovery. IFC on the back, TENS on the arm at 100 Hz, and IFC on the arm 
exhibited lower SBP during exercise and recovery, but were higher during occlusion. 
TENS on the back at 4 Hz exhibited the largest increase in SBP during exercise, which 
then decreased during occlusion and recovery compared to control. TENS on the arm at 4 
Hz exhibited lower SBP for exercise, occlusion, and recovery compared to control.  
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Figure 5.9: Diastolic blood pressure, measured as percent change from baseline reading, 
for all treatment conditions 
DBP was measured to determine if the metaboreflex was attenuated by TENS or 
IFC, i.e. reduced DBP would indicate a possible reduction in metaboreflex activation 
during a particular phase of the protocol. No statistical differences were found among the 
treatment conditions when compared with the control condition. However, TENS on the 
arm at 4 Hz and IFC on the back trended toward a higher DBP compared to control for 
exercise, occlusion, and recovery. TENS on the arm at 100 Hz and TENS on the back at 
100 Hz exhibited lower DBP during exercise and recovery, but were higher during 
occlusion. TENS on the back at 4 Hz exhibited the largest increase in DBP during 
exercise, which then decreased during occlusion and increased during recovery compared 
to control. IFC on the arm exhibited lower DBP for exercise, occlusion, and recovery 
compared to control.  
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Figure 5.10: Heart rate, measured as percent change from baseline reading, for all 
treatment conditions 
HR was measured to determine if TENS or IFC affected descending central 
controls from the brain, specifically the medulla oblongata, as any significant increase or 
decrease in HR would indicate activation of this region, most likely through vascular 
baroreceptor reflex arcs. No statistical differences were found among the treatment 
conditions when compared with the control condition. However, IFC on the back and 
TENS on the arm at 100 Hz trended toward a higher HR compared to control for 
exercise, occlusion, and recovery. TENS on the back at 4 Hz exhibited higher HR during 
exercise and recovery, but was lower during occlusion compared to control. TENS on the 
arm at 4 Hz exhibited higher HR during exercise and occlusion, but was lower during 
recovery. IFC on the arm nearly mirrored the trend for the control condition. TENS on 
the back at 100 Hz exhibited lower HR during exercise and occlusion, but was higher 
during recovery.  
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Figure 5.11: Estimated mean arterial pressure, measured as percent change from 
baseline reading, for all treatment conditions 
MAP was estimated as discussed in Section 5.1 to determine if the metaboreflex 
was attenuated by TENS or IFC, i.e. reduced MAP would indicate a possible reduction in 
metaboreflex activation during a particular phase of the protocol. No statistical 
differences were found among the treatment conditions when compared with the control 
condition. However, IFC on the back and TENS on the arm at 100 Hz trended toward a 
lower MAP during exercise and recovery, but were higher during occlusion compared to 
control. TENS on the back at 100 Hz exhibited higher MAP during occlusion and 
recovery, but was lower during exercise. TENS on the back at 4 Hz exhibited the highest 
increase in MAP during exercise, which then decreased during occlusion and recovery 
compared to control. TENS on the arm at 4 Hz and IFC on the arm exhibited lower MAP 
during exercise, occlusion, and recovery compared to control.  
 
 
-4
-2
0
2
4
6
8
10
12
Exercise Occlusion Recovery
M
ea
n
 A
rt
er
ia
l P
re
ss
u
re
 (%
 C
h
a
n
ge
)
Control TENS on Arm at 100 Hz TENS on Back at 100 Hz
TENS on Arm at 4 Hz TENS on Back at 4 Hz IFC on Back
IFC on Arm
78 
 
 
Figure 5.12: Estimated cutaneous vascular resistance in the left palm, measured as 
percent change from baseline reading, for all treatment conditions 
CVR was estimated in the palm as discussed in Section 5.1 to determine if the 
metaboreflex was attenuated by TENS or IFC i.e. reduced CVR would indicate a possible 
reduction in metaboreflex activation during a particular phase of the protocol. No 
statistical differences were found among the treatment conditions when compared with 
the control condition. However, TENS on the back at 100 Hz, TENS on the arm at 100 
Hz, TENS on the back at 4 Hz, and TENS on the arm at 4 Hz all trended toward a lower 
CVR during exercise, occlusion, and recovery compared to control. IFC on the back 
exhibited higher CVR during exercise and recovery, but was lower during occlusion 
compared to control. IFC on the arm exhibited the opposite trend with lower CVR during 
exercise and recovery, but higher CVR during occlusion compared to control.  
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Figure 5.13: Estimated cutaneous vascular resistance in the left anterior brachial region, 
measured as percent change from baseline reading, for all treatment conditions 
CVR was estimated in the anterior brachial region to correlate the changes in 
vascular resistance occurring downstream of the occluded region, i.e. the palm to changes 
upstream of this site. For example, if CVR in the left palm increased during occlusion, 
then a decrease in CVR in the left anterior brachial region would be expected, as blood 
flow is being redistributed to this ischemic region. No statistical differences were found 
among the treatment conditions when compared with the control condition. However, 
TENS on the back at 100 Hz trended toward a higher CVR compared to control for 
exercise, occlusion, and recovery. IFC on the back exhibited higher CVR during exercise 
and occlusion, but was lower during recovery compared to control. TENS on the arm at 4 
Hz exhibited higher CVR during exercise, but was lower during occlusion and recovery. 
TENS on the back at 4 Hz, IFC on the arm, and TENS on the arm at 100 Hz exhibited 
lower CVR during exercise, occlusion, and recovery compared to control.  
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5.3 Discussion 
 The goal of the pre-pilot work was to optimize the design for the eventual pilot 
study. The ideal parameters, i.e. frequency, pulse width, duration of treatment, and 
location of application, for a given neurostimulation technique that elicit the greatest 
beneficial hemodynamic changes, i.e. decreased blood pressure, increased blood flow, 
and decreased vascular resistance, are not well-established. Similarly, there has been very 
little research comparing the different neurostimulation techniques to one another in 
terms of these changes. Thus, the primary focus of this research was to investigate what 
parameters and neurostimulation technique should be used in the pilot study. Six different 
treatment conditions were compared to a control condition where the electrodes were 
applied to the skin but the unit was not turned on. Specifically, TENS at 4 Hz and 100 
Hz, and IFC at 100 Hz were all compared. Two different locations for electrode 
placement were compared, the back at the C7 and T4 dermatomes and the forearm at the 
proximal and distal regions.  
 From the results obtained, a complete assessment of which treatment condition 
worked “best” is unattainable, as the treatment conditions did not exhibit statistically 
significant differences from the control condition, besides IFC on the back, which 
exhibited a significantly lower reperfusion time compared to control. The reason for this 
lack of statistical significance for the rest of the hemodynamic parameters is most likely 
due to the small sample sizes used for the different treatment groups, rather than a lack of 
effectiveness of the actual treatment. Nevertheless, the trends shown in Figures 5.4 
through 5.13 suggest which treatment condition may be the most effective and which 
conditions should be ruled out based on their potential adverse effects. Application of 
TENS on the arm at 100 Hz trended towards increased pain intensity during exercise and 
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occlusion. Although this condition trended towards increased CBF and decreased CVR, 
any treatment condition that increases pain intensity compared to control should not be 
utilized for the pilot study. The reason for this is that participants will be able to opt out 
of the experiment if they reach their personal pain tolerance threshold, so we want to 
ensure that we do not cause any additional/unnecessary pain besides the induced-
ischemic pain. For this same reasoning, application of TENS on the back at 4 Hz should 
not be further pursued as it too trended towards increased pain intensity. It was also the 
only treatment condition that trended towards a longer reperfusion time than control as 
well as a higher MAP during exercise. Excluding these two treatment conditions, TENS 
on the arm at 4 Hz trended towards favorable hemodynamic changes, such as lower 
reperfusion time, pain intensity, CVR in the anterior brachial region and in the palm, 
MAP, SBP, and higher CBF in the anterior brachial region compared to control. TENS 
on the back at 100 Hz also trended towards favorable hemodynamic changes, such as 
lower reperfusion time, pain intensity, CVR in the palm, HR, DBP, and higher CBF in 
the palm compared to control. This is in accordance with work by Vieira et al, in which 
decreases in MAP, increases in blood flow, and decreases in vascular resistance with 
application of TENS on the back at 80 Hz were found in their younger aged group [81], 
although MAP was higher than control during occlusion and recovery in our own study. 
These results cannot be directly compared, since both the TENS parameters and 
perfusion measurement instrumentation used in our study and in the study by Vieira et al 
were different, e.g. blood flow was measured in the calf using venous occlusion 
plethysmography rather than in the palm and anterior brachial region using LDF. 
Furthermore, MAP was continuously monitored using a Dinamap blood pressure monitor 
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rather than estimated from SBP and DBP. From our own results, it seems that a low 
stimulation frequency is more effective when TENS is applied on the forearm, while a 
high stimulation frequency is more effective when TENS is applied on the back. It was 
expected that a high frequency would be more effective, regardless of electrode 
placement, but it is possible that a high frequency on the forearm activates Aδ-fibers 
responsible for the sharp pain sensation, which could also stimulate the SNS further. The 
high frequency on the back may be more effective than a low frequency, because it is 
capable of causing maximum suppression of the C-fibers, which allows for higher 
intensities to be used; thus, current travels farther along the dermatomes to the ischemic 
site, providing more local pain relief and vasodilation. Application of IFC on the arm 
presented the most consistent beneficial hemodynamic changes compared to the other 
treatment conditions, i.e. the data trended towards increased blood flow to the palm and 
anterior brachial region, decreased MAP, decreased CVR in the anterior brachial region, 
decreased pain intensity throughout the experiment, decreased reperfusion time, and it 
did not change HR. This was expected based on the hypothesis that IFC stimulates deeper 
muscle afferents, which further reduces noxious stimulus transmission and metaboreflex 
activation. The only concerning aspect of this treatment condition was that CVR in the 
palm increased slightly during occlusion compared to control, while all other treatment 
conditions decreased during this interval, Nevertheless, CVR trended towards lower 
values during exercise and recovery for IFC on the arm compared to control. Although 
not shown in Figure 5.12, the standard error during the occlusion phase was large, so 
there may be random effects from subject variation, or the standard error may result 
solely from experimental error. Application of IFC on the back also had promising results 
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with the greatest reductions in pain and CVR in the palm, as well as a significant 
decrease in reperfusion time compared to control, although CBF trended towards lower 
values in the palm and anterior brachial regions as compared to control. This significant 
decrease in reperfusion time indicates either that blood flow redistribution to the palm 
after occlusion was improved compared to control and/or that it took less time to reach 
the average baseline perfusion value because the percent change during recovery was 
lower than the rest of the treatment conditions. In work by Santos et al, the effect of IFC 
on the back at 100 Hz was also investigated and they found statistically significant 
decreases in MAP, increases in blood flow, and decreases in vascular resistance. MAP 
trended towards lower values in our own study during exercise and recovery, but 
increased during occlusion compared to control. Although CVR in the palm trended 
towards lower values, CBF did as well, so our results do not show the same trends as 
Santos’s study, although it should be noted that venous occlusion plethysmography was 
used to measure blood flow in the calf and the treatment duration was 30 minutes rather 
than 15 minutes [126].  Regardless, it seems that IFC did produce more favorable 
hemodynamic changes overall than TENS.  
While conducting the pre-pilot work, a number of potential possibilities for 
experimental error were observed, all of which must be carefully considered and 
addressed before performing the pilot study. The most significant error we observed were 
fluctuations in blood flow readings not caused by the treatment condition itself during 
some of the experiments. For example, ambient temperature affects skin temperature and 
skin temperature can affect blood flow [204]. During our research, we noticed that 
fluctuations in room temperature could affect the skin temperature readings that we 
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recorded from the LDF system, although to what extent was not determined in our 
research. Thus, blood flow may also have been affected by these fluctuations in room 
temperature. In order to mitigate this potential error, skin temperature was recorded 
before and after the treatment session to determine if any appreciable change had 
occurred. So long as the skin temperature remained within ± 1°C, the results were kept 
for that individual session. If the temperature had fluctuated beyond this range, a new 
treatment session would have been conducted again and compared to the previous session 
to determine if there were significant differences between the two, but this did not occur. 
The blood flow readings can also be affected by any kind of motion artifact, such as from 
breathing, movement of the limbs, or vibrations from other equipment/other sources. 
Luckily, this motion artifact is relatively easy to identify in LabChart. For instance, major 
spikes in blood flow can be seen from both skin probes if the subject moves their arm. 
These spikes can be deleted from the data trace, so that they do not affect the results. The 
blood flow reading will change based on where the probe is positioned, so much so that 
even a millimeter difference in probe placement can affect the reading by as much as 200 
perfusion units (PU). This is why percent changes from baseline must be taken for LDF 
measurements, not to mention there is inter-individual variation and day-to-day variation 
in these measurements as well. The reason for this day-to-day variation may be due to 
prior exercise, lack of sleep, hunger, dehydration, sickness, stress, and caffeine 
consumption. The blood pressure measurements that were taken for this study were not 
conducted in the most ideal manner. Most current research in this field uses continuous 
blood pressure monitors, such as Finometers, because they provide a real-time 
measurement that can be averaged over each interval of the experiment. MAP and CVR 
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can then be accurately calculated from these measurements [66, 81, 112, 126, 156]. These 
systems are very expensive (~$25-30k, based on quotes obtained from ADInstruments 
and Finapres), however, and could not be purchased for this study. We used a digital 
blood pressure monitor, as specified in Section 5.1, which is accurate to ± 3 mmHg. The 
estimation of MAP described in Section 5.1 is acceptable, so long as HR remains below 
100 beats⋅minute-1 [205], and is more applicable for healthy, younger individuals [206]. 
Gripping of the hand dynamometer for the “exercise” portion of the treatment session did 
not cause HR to rise above this level. Lastly, the TENS parameters still have not been 
optimized based on the mixed results obtained, but IFC using the parameters specified in 
Table 5.1 seems to be more effective based on the trends observed for each 
hemodynamic parameter.  
For the pilot study, it will be imperative to keep the room where the treatment 
sessions will be held as controlled as possible. Because temperature can affect CBF, the 
room should have a thermostat or other device capable of maintaining a constant 
temperature. The room should also be clear of any audio or visual distractions that may 
influence the participant’s BP, HR, etc. The potential for motion artifact should be 
reduced by ensuring all cables are not overlapping with others or resting on the 
participant, if possible. Participant comfort should be a primary focus during the 
treatment session. In our pre-pilot work, the participant rested their arms on a pillow to 
ensure comfort and that pressure was evenly distributed across the forearm from the 
blood pressure cuff. Having the participant lay in a supine position may be even better for 
ensuring optimal comfort, rather than having them sit in a chair during the duration of the 
treatment, and was done in a few studies for this reason [81, 112, 126, 156, 207]. 
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However, this may induce stronger parasympathetic activity, i.e. lower BP and HR [208]. 
Using the new MEDITEC budget for the next school year, it may be worthwhile to 
purchase a continuous blood pressure monitor, so that MAP and CVR can be calculated 
with confidence, rather than estimating both. Before the pilot study is conducted, further 
investigation is still needed into the relative effectiveness of IFC and TENS, and what set 
of parameters produces consistent, statistically significant hemodynamic changes. 
Specifically, low intensity (sensory threshold), high frequency (100 Hz) TENS and IFC 
should be compared to high intensity (motor threshold), low frequency (4 Hz) TENS and 
IFC. Treatment duration should also be compared at 15 minutes and 30 minutes, as well 
as determining how long the hemodynamic changes last. The electrode placement sites 
should be compared on the forearm and on the back as done in our pre-pilot experiments. 
Blood flow in the contralateral limb and/or the calf should also be measured to determine 
if neurostimulation causes systemic vasodilation or if it is only at the site of application. 
Many of these parameters have been investigated in terms of analgesic effects, but not 
hemodynamic effects [202, 209-211]; thus, future pre-pilot experiments should 
investigate all these different parameters (Figure 5.14). This work should build off the 
work conducted by our own group, when possible, so that results may be combined to 
increase the overall sample size. The research conducted by our own group has shown 
that both TENS and IFC may produce favorable changes on the cardiovascular system in 
ischemia- induced subjects. Whether these changes have a favorable impact on patients 
with actual ischemia, such as in the case of PAOD, is still yet to be seen. Thus, the pilot 
study will provide important information on the use of neurostimulation to treat ischemia, 
which may warrant further clinical investigation.  
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Figure 5.14: Diagram detailing the pre-pilot work that still needs to be conducted and 
what specific parameters should be analyzed before the pilot study 
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APPENDICES 
Appendix A: Summary of Select Neurostimulation Studies on Hemodynamics  
 
Table A.1: Summary of TENS studies 
Study 
Author 
Year 
Purpose Model 
Animal/Human 
Healthy/Diseased 
Neurostimulation 
Parameters Used 
Intensity 
Pulse width 
Frequency 
Duration 
Location 
Endpoints* Possible Mechanism(s) of Action 
Ter Laan [67] 
2010 
  
Assessed the effect of 
TENS on cerebral 
blood flow and its 
potential side-effects; 
investigated the effects 
of varying frequency 
and hyperventilation; 
accounted for 
differences in age and 
gender 
Human 
Healthy 
90% of highest 
tolerated current (about 
10 to 35 mA)  
200 µs 
2, 20, 50, 100 and 120 
Hz 
5 minutes at each 
frequency 
Applied to the 
dermatome at C2-C3 
MAP; HR; CBFV; 
ETCO2 
Either directly affects vascular 
diameter or indirectly affects 
sympathetic tone 
Sanderson [80] 
1995 
 
 
Assessed the effect of 
TENS on autonomic 
cardiovascular reflexes 
through noninvasive 
tests i.e. tilt study, cold 
face stimulus, 
Valsalva’s maneuver, 
handgrip test, and 
supine resting 
Human  
Healthy 
Motor intensity 
200 µs 
150 Hz  
~ 35 minutes 
Applied to center of 
chest and back 
SBP; DBP; MAP; 
HR 
Mild effect on autonomic reflexes; 
more effective during exercise when 
sympathetic tone is more strongly 
stimulated; possibly blocking or 
interfering with vascular reflex 
response within spinal cord 
                                                                 
 
* MAP = Mean Arterial Pressure; HR = Heart Rate; CBFV = Cerebral Blood Flow Velocity; ETCO 2 = End-Tidal Carbon Dioxide Concentration; SBP = Systolic Blood 
Pressure; DBP = Diastolic Blood Pressure 
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Study 
Author 
Year 
Purpose Model 
Animal/Human 
Healthy/Diseased 
Neurostimulation 
Parameters Used 
Intensity 
Pulse width 
Frequency 
Duration 
Location 
Endpoints* Possible Mechanism(s) of Action 
Chauhan [33] 
1994 
Assessed whether 
TENS can relieve 
ischemia associated 
with angina pectoris 
by increasing coronary 
blood flow; accounted 
for gender differences 
and different disease 
states 
Human 
Diseased (Syndrome 
X and CAD) and 
“Healthy” (heart 
transplant patients) 
10-60 mA 
300 µs 
150 Hz 
5 minutes  
Chest near pain location 
CBFV; HR; MAP; 
SBP; coronary 
artery diameter; 
epinephrine/norepi
nephine levels 
May affect coronary microvascular 
tone as a result of changes in neural 
tone resulting in increased coronary 
blood flow; decreased sympathetic 
activity within the heart 
Mannheimer [36] 
1990  
 
 
Assessed effect of 
TENS on the 
sympathetic nervous 
system; administered 
naloxone to determine 
if natural opioid 
release could be a 
possible mechanism of 
action 
Human 
Diseased  
Study I: Pacing-
induced angina 
pectoris (Class III or 
IV) 
Study II: Pacing-
induced angina 
pectoris (Class III or 
IV) and CAD 
30-50 mA 
200 µs 
70 Hz 
15 minutes 
Painful area of chest 
Left ventricular 
afterload; SBP; 
DBP; myocardial 
lactate metabolism; 
systemic and 
pulmonary 
resistance; oxygen 
saturation; stroke 
volume index; 
cardiac index; HR; 
concentrations of 
epinephrine and 
norpepinephrine 
Study I: Decrease in sympathetic 
activity due to drop in arterial levels 
of epinephrine and norepineprhine;  
Study II: No change in SBP or levels 
of epinephrine and norepinephine; not 
mediated by beta-endorphins; may 
activate delta or kappa receptor 
agonists 
                                                                 
 
* MAP = Mean Arterial Pressure; HR = Heart Rate; CBFV = Coronary Blood Flow Velocity; SBP = Systolic Blood Pressure; DBP = Dias tolic Blood Pressure 
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Study 
Author 
Year 
Purpose Model 
Animal/Human 
Healthy/Diseased 
Neurostimulation 
Parameters Used 
Intensity 
Pulse width 
Frequency 
Duration 
Location 
Endpoints* Possible Mechanism(s) of Action 
Sherry [66] 
2001 
 
 
Assessed the effect of 
burst-mode TENS on 
calf blood flow, 
arterial pressure, and 
skin temperature 
Human 
Healthy 
Motor intensity 
250 µs 
Burst frequency: 2 
bursts per second 
Carrier frequency: 85 
Hz 
5 minutes  
Peroneal and tibial 
nerves 
CBF; MAP; skin 
temperature; 
ETCO2; BP; CVR 
Depends on stimulation intensity 
whereby a higher intensity can cause 
muscle contraction and a transient, 
local increase in blood flow via 
accumulation of metabolic vasodilator 
substances and/or release of “relaxing 
factors” from endothelium 
Cramp [63] 
2000  
 
 
Assessed the effect of 
both high and low 
frequency TENS on 
local cutaneous blood 
flow and skin 
temperature 
Human 
Healthy 
Sensory intensity 
200 µs 
Low (4 Hz) and high 
(110 Hz)  
15 minutes 
Median nerve of 
forearm 
Forearm blood 
perfusion; skin 
temperature 
Low frequency stimulation elicits a 
local increase in cutaneous blood flow 
as a result of vasodilation but does not 
affect skin temperature; may partially 
inhibit the sympathetic nervous 
system 
 
 
 
                                                                 
 
* MAP = Mean Arterial Pressure; BP = Blood Pressure; CBF = Calf Blood Flow; CVR = Calf Vascular Resistance; ETCO 2 = End-Tidal Carbon Dioxide Concentration 
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Study 
Author 
Year 
Purpose Model 
Animal/Human 
Healthy/Diseased 
Neurostimulation 
Parameters Used 
Intensity 
Pulse width 
Frequency 
Duration 
Location 
Endpoints* Possible Mechanism(s) of Action 
Vieira [81] 
2012  
Assessed the effect of 
TENS on 
metaboreflex 
activation and HRV in 
both young and older 
subjects 
Human 
Healthy  
 
Sensory intensity 
150 µs 
80 Hz 
30 minutes 
C7 and T4 vertebral 
levels  
HR; MAP; CBF; 
CVR; HRV 
Blunted muscle metaboreflex, reduced 
sympathetic activity, and 
improvement of the sympatho-vagal 
balance with application of TENS, 
especially in younger individuals; 
metaboreflex may be attenuated in 
older subjects 
Indergand [207] 
1994 
Assessed the effect of 
TENS on limb blood 
flow; compared both 
sensory and motor 
intensities  
Human 
Healthy 
Both sensory and motor 
intensity 
150 µs 
110 Hz 
20 minutes 
Left common peroneal 
nerve and left tibial 
nerve 
CBF; MAP; CVR; 
skin temperature 
Both sensory and motor intensity 
levels of TENS failed to elicit any 
changes in CBF, MAP, or CVR; skin 
temperature decreased during both 
control and TENS 
                                                                 
 
* MAP = Mean Arterial Pressure; HR = Heart Rate; CBF = Calf Blood Flow; CVR = Calf Vascular Resistance; HRV = Heart Rate Variab ility  
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Table A.2: Summary of SCS studies 
Study 
Author 
Year 
Purpose** Model 
Animal/Human 
Healthy/Diseased 
Neurostimulation 
Parameters Used 
Intensity 
Pulse width 
Frequency 
Duration 
Location 
Endpoints* Possible Mechanism(s) of Action** 
Tallis  [37] 
1983 
 
 
Assessed whether 
SCS could 
potentially 
improve clinical 
outcomes for 
PAOD patients; 
compared to 
placebo and 
TENS as well 
Human 
PAOD 
8 mA 
200 µs 
33 Hz 
Varied on the order of 
months 
Not indicated 
Claudication distance; 
exercise tolerance using 
bicycle ergometer; 
CBF; MBF 
 
 
Inhibits vasoconstriction; antidromic 
stimulation of sensory neurons may 
cause release of prostaglandins and 
prostacyclins in muscle 
 
Gao [97] 
2010 
Assessed the 
effect of SCS on 
peripheral 
vasodilation at 
different 
frequencies; used 
RTX and CGRP8–
37 to try to 
elucidate 
mechanisms   
Rats  
Healthy 
30%, 60%, and 90% of 
motor intensity  
200 µs 
50, 200, and 500 Hz 
2 minutes 
L2 - L3 vertebral levels 
CBF; MAP; CVR CGRP8–37 blocks vasodilation 
induced by SCS; 
SCS activates TRPV1-containing 
sensory neurons to release 
vasodilators; indirectly induces 
release of NO; both antidromic and 
sympathetic inhibition mechanisms 
at work; higher frequencies i.e. 500 
Hz cause more vasodilation 
 
 
 
 
                                                                 
 
* MAP = Mean Arterial Pressure; CBF = Cutaneous Blood Flow; CVR = Cutaneous Vascular Resistance; CGRP = Calcitonin Gene-Related Peptide; TRPV1 = 
Transient Receptor Potential Vanilloid-1; NO = Nitric Oxide; RTX = Resiniferatoxin  
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Study 
Author 
Year 
Purpose†† Model 
Animal/Human 
Healthy/Diseased 
Neurostimulation 
Parameters Used 
Intensity 
Pulse width 
Frequency 
Duration 
Location 
Endpoints* Possible Mechanism(s) of Action 
Augustinsson [32] 
1985 
Assessed the 
potential for SCS 
as a treatment for 
PAOD and 
whether it reduced 
the number of 
amputations 
Human  
PAOD/diabetic; 
Buerger’s disease; 
vasospastic 
disorders 
Varied 
200 µs 
100 Hz 
~15 months 
T10 vertebral level for 
affected legs, T3 and 
C5 for affected arms  
SBP; skin temperature; 
systolic toe pressure; pain 
relief (qualitative); number 
of amputations; healing of 
ulcers; thumb pressure 
Suppresses vasospasm in addition to 
pain; stimulation may cause 
prostaglandin release having a local 
dilatory effect on the vasculature or it 
may simply block the noxious signal 
which would decrease sympathetic 
tone; may release segmental spinal 
reflexes causing sympatholysis 
within  vessels in the extremities  
Croom [96] 
1997 
Assessed the 
effect of SCS on 
cutaneous 
vasodilation, 
specifically in 
regards to the 
release of CGRP 
and substance P; 
investigated 
whether 
rhizotomy of the 
dorsal roots would 
attenuate the 
induced 
vasodilation 
Rats 
Healthy 
0.2 or 0.6 mA 
200 µs 
50 Hz 
1 minute 
L1 – L2 vertebral levels  
CBF; CVR; MAP Vasodilation caused by release of 
CGRP into the periphery via 
antidromic activation of sensory 
afferents in the dorsal roots, 
specifically L3 – L5 dorsal roots are 
necessary for increased cutaneous 
hindpaw blood flow; substance P 
does not play a major role in the 
vasodilatory response  
                                                                 
 
* MAP = Mean Arterial Pressure; CBF = Cutaneous Blood Flow; CVR = Cutaneous Vascular Resistance; CGRP = Calcitonin Gene-Related Peptide; SBP = Systolic 
Blood Pressure 
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Table A.3: Summary of EA studies 
 
Study 
Author 
Year 
Purpose Model* 
Animal/Human 
Healthy/Diseased 
Neurostimulation 
Parameters Used 
Intensity 
Pulse width 
Frequency 
Duration 
Location 
Endpoints* Possible Mechanism(s) of Action 
Lin [112] 
2003 
Assessed whether 
EA has a depressor 
effect on the 
cardiovascular 
system 
Human 
Healthy  
5x above sensory intensity 
50 µs 
2 Hz  
3 minutes 
“Hoku” point (LI-4) i.e. 
between index finger and 
thumb 
 
BP, PVT, FBF, HR Increased PVT explained by decreased 
response of sympathetic nerve system, 
which caused dilation of arterioles; BP 
and FBF decreased while HR increased  
 
Zhou [68] 
2013  
Assessed whether 
EA-induced 
cerebral protection 
against ischemia 
was dependent on 
stimulation of 
certain acupoints 
Rats 
Induced cerebral 
ischemia via 
MCAO 
1 mA 
500 µs 
5 Hz or 20 Hz 
30 minutes 
4 different acupoints: DU-
26 & DU-20, left LI-11 & 
PC-6, right LI-11 & PC-6, 
and left GB-34 & SP-6 i.e. 
head, face, anterior limbs 
Infarct volume; death 
rate; neurological 
deficits; CBF 
Location of stimulation can have a 
protective effect against cerebral 
ischemia possibly via regulation of 
neurotransmitter release, causing an 
increase in blood flow, but only in 
ischemic conditions 
 
 
 
                                                                 
 
*CBF = Cerebral Blood Flow; BP = Blood Pressure; PVT = Paravertebral Temperature; FBF = Finger Blood Flow; HR = Heart  Rate; MCAO = Middle Cerebral Artery 
Occlusion 
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Study 
Author 
Year 
Purpose Model* 
Animal/Human 
Healthy/Diseased 
Neurostimulation 
Parameters Used 
Intensity 
Pulse width 
Frequency 
Duration 
Location 
Endpoints* Possible Mechanism(s) of Action 
Noguchi 
[113] 
1999 
Assessed whether 
EA stimulation 
could induce 
changes in muscle 
blood flow and 
determined which 
somatic afferent 
fibers were 
responsible for 
these changes 
Rats 
Healthy 
 
0.1-10 mA 
500 µs 
1-20 Hz 
30 seconds 
Left and right hindpaws 
MBF; MAP; RBF Stimulation of group III and IV 
afferent fibers in saphenous and tibial 
nerves produces an increase in MBF in 
conjunction with an increase in 
systemic MAP; splanchnic nerve 
severance decreases MBF suggesting 
group III and IV afferent fibers 
primarily excite a vasoconstrictive 
response; the pressor response still 
dominates in muscles causing more 
vasodilation than vasoconstriction; 
stimulation of group I and II afferent 
fibers seems to be ineffective 
Kimura [64] 
2008 
Assessed the effect 
of EA on the 
rhythmicity of the 
autonomic nervous 
system 
Canine Healthy 5V 
250 µs 
2 Hz 
15 minutes 
“Xuan Shu” (GV-5) and 
“Bai Hui” (GV-20) i.e. T13-
L1 and L7-S1 spinal 
segment levels 
 
HR; CVRR; LF/HF; 
HRV 
Activates sympathetic nervous 
activities as evidenced by increase in 
LF/HF ratio 
 
                                                                 
 
*MAP = Mean Arterial Pressure; HR = Heart Rate; RBF = Renal Blood Flow; MBF = Muscle Blood Flow; CVRR = Coefficient of Variati on in R-R Intervals; LF/HF = 
Low-Frequency/High Frequency (components of HRV); HRV = Heart Rate Variability  
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Table A.4: Summary of IFC studies 
Study 
Author 
Year 
Purpose Model 
Animal/Human 
Healthy/Diseased 
Neurostimulation 
Parameters Used 
Intensity 
Pulse width 
Frequency 
Duration 
Location 
Endpoints* Possible Mechanism(s) of Action 
Johnson [119] 
2003 
Assessed the analgesic  
effects of both IFC 
and TENS on induced 
ischemic pain 
Human 
Healthy 
Sensory intensity 
200 µs 
100 Hz 
22 minutes 
Anterior and posterior 
aspects of forearm  
Amount of pain 
experienced (VAS & 
MPQ scores) 
Selective activation of A-beta 
nerve fibers 
Noble [125] 
2000 
 
 
Assessed the effect of 
varying frequency of 
IFC on CBF 
Human 
Healthy 
Sensory intensity 
125 µs 
10-100, 80-100, and 10-20 
Hz 
15 minutes 
Medial and lateral aspects of 
the thigh 
Skin temperature; CBF  Low frequency (10-20 Hz) causes 
increases in CBF and skin 
temperature through inhibition of 
the sympathetic nervous system 
Santos  [126] 
2013 
 
Assessed the effect of 
IFC on muscle 
metaboreflex 
activation and 
peripheral vasodilation 
Human  
Healthy 
Sensory intensity 
Not indicated 
100 Hz 
30 minutes 
C7 and T4 spinal segments  
MAP; HR; CBF; CVR; 
metaboreflex activity 
Decrease in MAP and metaboreflex 
activity indicates reduction in 
sympathetic tone; reduced CVR 
and increased CBF   
                                                                 
 
*MAP = Mean Arterial Pressure; HR = Heart Rate; RBF = Renal Blood Flow; MBF = Muscle Blood Flow; CVRR = Coefficient of Variati on in R-R Intervals; LF/HF = 
Low-Frequency/High Frequency (components of HRV); HRV = Heart Rate Variabil ity  
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Appendix B: Informed Consent Form 
INFORMED CONSENT TO PARTICIPATE IN A RESEARCH PROJECT: “Determining Limb 
Blood Flow Changes in Response to Electrical Neurostimulation”.  
 A research project on peripheral blood flow and ischemic pain is being conducted by 
Sean Youra and Stacey Fishman in the Department of Biomedical Engineering at Cal Poly, San 
Luis Obispo.  The purpose of the study is to measure changes in blood flow, heart rate, and blood 
pressure due to the application of electrical neurostimulation.  
 You are being asked to take part in this study by first filling out a short medical history 
questionnaire. Questions marked with an asterisk (*) are required, but any others you do not wish 
to answer may be omitted. These questions are directly related to your safety. During each 
treatment session, you will be hooked up to a neurostimulation device that will be attached to 
your upper back with electrodes, a blood flow measurement system using skin probes on the 
upper arms, a respiration belt wrapped around your midsection, and a blood pressure cuff applied 
to each arm. Appropriate clothing should be worn to ensure proper placement of the electrodes, 
and a researcher from the same gender will be there to place the electrodes on your upper back. 
You will be asked to squeeze a handgrip force measurement device for a short period of time. 
You will experience electrical stimulation from the attached electrodes, which you may feel as a 
warm, tingling sensation on your back. Your participation will take approximately 1 hour in two 
separate sessions on two different days, which includes a 30-minute break in-between each 
session, for a total of approximately 2 hours. In some of these sessions, the neurostimulation 
device will be hooked up to you, but no current will be applied, as in you will not feel any 
sensation on your back. This will be randomized. Please be aware that you are not required to 
participate in this research and you may discontinue your participation at any time without 
penalty.  
 The possible risks associated with participation in this study include pain due to 
temporarily induced ischemia i.e. insufficient blood flow to the tissue, skin irritation from the 
application of skin probes and electrodes, and possible discomfort and/or stress from gripping the 
hand force measurement device. If your personal pain tolerance threshold is reached at any point, 
you may discontinue your participation immediately. If you should experience residual pain or 
tingling after the duration of the experiment or an allergic reaction at the site of the probes or 
electrodes, please be aware that you may contact Cal Poly Health and Counseling Services, 
located in building 27, at (805) 756-1211 for assistance. 
 Your confidentiality will be protected by recording your medical history, age, gender, 
height and weight on a document with a corresponding code. This document will be kept as a 
hard copy only and separate from the corresponding list of codes. Your information will only be 
accessible to the researchers in this study. If the results of the study are published, any identifying 
information will be omitted. There are no direct benefits to you associated with this study. 
Depending on the outcome of the study, this could become an additional treatment method for 
individuals with ischemic pain.  
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If you have questions regarding this study or would like to be informed of the results 
when the study is completed, please feel free to contact Sean Youra at (949) 697-5789, Stacey 
Fishman at (860) 338-4085, or Dr. Trevor Cardinal at (805) 756-6244.  If you have concerns 
regarding the manner in which the study is conducted, you may contact Dr. Steve Davis, Chair of 
the Cal Poly Human Subjects Committee, at (805) 756-2754, sdavis@calpoly.edu, or Dr. Dean 
Wendt, Interim Dean of Research, at (805) 756-1508, dwendt@calpoly.edu. 
 If you agree to voluntarily participate in this research project as described, please indicate 
your agreement by signing below.  Please keep one copy of this form for your reference, and 
thank you for your participation in this research. 
 
____________________________________   ________________ 
                   Signature of Volunteer                               Date 
 
____________________________________   ________________ 
                   Signature of Researcher                              Date 
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Appendix C: Medical History And Screening Form 
* Required 
General Information 
Participant: 
Sex: 
     
Women only answer the following: 
        Yes   No 
 
 
Men and women answer the following: 
_______________________________________________________________________  
_______________________________________________________________________  
 
_______________________________________________________________________ 
 
_______________________________________________________________________ 
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Past Medical History 
* Required 
Have you ever had any of the following: 
        Yes   No 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Smoking 
 
Drinking 
 
 
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Appendix D: Numeric Pain Rating Scale 
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Appendix E: Protocol For The Pilot Study 
 Setup 
 Turn on the laptop. 
 Connect the power supply to PowerLab.  
 Connect the USB cable from PowerLab to the laptop.  
 Connect the respiration belt to Input 1 on the front panel of PowerLab. 
 Connect the Hand Dynamometer to Input 2 on the front panel of 
PowerLab.  
 Connect the power supply to the Laser Doppler Flow (LDF) system and 
turn it on.  
 Connect the skin probes to Channels 1 and 2 on the LDF system. 
 Connect the BNC cables from the LDF system to Inputs 3 and 4 on the 
front panel of PowerLab.  
 Turn on the PowerLab system. 
 Open LabChart on the laptop and open the customized settings file. 
 The raw breath signal in millivolts (mV), the respiratory rate in breaths per 
minute (BPM), the handgrip force in Newtons (N), CBF 1 in perfusion 
units (PU), and CBF 2 in PU should all be displayed in LabChart at this 
point.  
 Application 
 Seat the participant in a chair with both arms supinated and gently resting 
on the pillow. Ensure that they are comfortable and properly positioned 
before continuing.  
 Instruct the participant to loosely grip the Hand Dynamometer in the fist 
of their left hand.  
 Instruct the participant to squeeze the Hand Dynamometer as hard as 
possible for a second or two, and then relax their grip.* 
 Determine Maximum Voluntary Contraction (MVC) by recording the 
average of three handgrip trials and calculate 25% of MVC. 
 Apply the TENS electrodes to the C7 and T4 vertebrae locations, 
approximately 3 cm to the left and right of the vertebral column (Figure 
4.4).† 
                                                                 
 
* Adapted from BMED 460 – “Muscle Stimulation Fatigue Student Protocol” by Trevor Cardinal 
 
† Adapted from "Effect of transcutaneous electrical nerve stimulation on muscle metaboreflex in healthy 
young and older subjects." by Vieira, et. al. 
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Figure D.1: TENS Electrode Placement at the C7 and T4 Regions* 
 Wrap the respiration belt around the participant’s chest, just below the 
xiphoid process. 
 Attach the skin probe connected to Channel 1 of the LDF system to the 
left arm, 2 cm below the crease of the wrist.  
 Attach the skin probe connected to Channel 2 of the LDF system to the 
right arm, 2 cm below the crease of the wrist.  
 Wrap the cuff connected to the manual sphygmomanometer around the 
participant’s left forearm, 2 cm below the crease of the elbow. 
 Wrap the cuff connected to the blood pressure monitor around the 
participant’s right arm. 
 Set the stimulation frequency to 100 Hz, pulse duration to 200 μs, and 
slowly adjust the intensity to just above sensory threshold (no pain or 
muscle contraction) by asking the participant when he/she begins to feel a 
strong, but comfortable tingling sensation.  
 Treatment 
 Begin treatment according to assigned group code.† 
 Every minute, assess the intensity of the participant’s pain via the NPRS. 
In addition, halfway through each interval of the treatment i.e. “baseline”, 
                                                                 
 
* Adapted from "Effect of transcutaneous electrical nerve stimulation on muscle metaboreflex in healthy 
young and older subjects." by Vieira, et. al. 
 
† Group codes: Control/PECO- (CP-), Control/PECO+ (CP+), TENS/PECO- (TP-), TENS/PECO+ (TP+) 
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“exercise”, “occlusion”, and “recovery”, record the participant’s blood 
pressure and heart rate from the monitor. 
 Begin recording baseline blood flow for 3 minutes.  
 Place the hand dynamometer in the participant’s left hand. Instruct the 
participant to perform a static handgrip exercise for 3 minutes at 25% 
MVC. 
 Five seconds before exercise completion, inflate the sphygmomanometer 
cuff to 180 mmHg.* 
 Maintain cuff inflation at 180 mmHg for 3 minutes, while still recording 
blood flow.  
 Deflate the cuff immediately and record for 3 minutes. 
 Stop recording.  
 Insert comments for “baseline”, “exercise”, “occlusion”, and “recovery” at 
the end of each interval.  
 Detach all equipment from the participant and wait at least 30 minutes 
before beginning the next treatment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                 
 
* Only if PECO+ group 
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Appendix F: Averages From Pre-Pilot Work 
Table F.1: Average percent change for all hemodynamic parameters for each treatment 
condition 
 Exercise Occlusion Recovery 
Control (n = 20)    
CBF 1 20.61408 -90.1396 70.7512 
CBF 2 6.181795 10.56105 -7.52406 
SBP 4.922132 2.513589 1.065731 
DBP 4.045545 4.212532 2.391328 
HR 4.116884 4.732632 -0.72447 
MAP 4.343151 3.420077 1.658637 
CVR 1 1.979512 1258.739 -36.7768 
CVR 2 -1.34234 -3.54692 12.89023 
TENS Application 
on the Back at High 
Frequency (n = 6) 
   
CBF 1 25.43661 -81.5803 185.0897 
CBF 2 -5.5738 -12.4239 -8.40812 
SBP 6.04962 5.324572 5.120653 
DBP 0.036075 5.411255 -0.03608 
HR 2.698413 -2.43386 2.195767 
MAP 2.595939 5.37299 2.147184 
CVR 1 -18.2172 570.4271 -54.2402 
CVR 2 11.68384 21.19491 13.07613 
TENS Application 
on the Forearm at 
High Frequency (n 
= 2) 
   
CBF 1 16.45631 -80.0942 114.3978 
CBF 2 17.8305 24.17139 2.384457 
SBP 0.81187 2.874207 -4.04069 
DBP 3.159981 5.538713 0.034981 
HR 8.249337 6.618037 2.122016 
MAP 2.145089 4.337402 -1.7909 
CVR 1 -5.08757 597.8964 -45.3314 
CVR 2 -12.8027 -13.8696 -3.84971 
TENS Application 
on the Back at Low 
Frequency (n = 2) 
   
CBF 1 84.16821 -77.4402 259.6295 
CBF 2 14.21466 14.37029 4.612285 
SBP 10.29571 -3.0833 0.531915 
DBP 9.732163 2.34357 2.574463 
HR 9.254386 2.675439 5.921053 
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MAP 9.975071 -0.03917 1.698718 
CVR 1 -10.7307 802.1998 -52.9969 
CVR 2 -3.47213 -10.4482 -2.73357 
TENS Application 
on the Forearm at 
Low Frequency (n 
= 2) 
   
CBF 1 44.57743 -82.7889 72.09013 
CBF 2 5.046217 19.99818 -6.70987 
SBP 0.423812 -5.45535 -1.87759 
DBP 6.737288 4.265537 3.418079 
HR 4.312039 5.454545 -5.42998 
MAP 3.67893 -0.19509 1.161278 
CVR 1 -16.3281 1184.719 -34.5453 
CVR 2 0.07898 -16.9482 9.427779 
IFC Application on 
the Back (n = 2) 
   
CBF 1 -15.2391 -80.6055 3.330334 
CBF 2 1.131429 -1.04201 -0.52675 
SBP -1.40911 6.140351 -0.90519 
DBP 6.299841 5.023923 2.232855 
HR 13.95161 8.225806 8.252688 
MAP 2.753674 5.581614 0.869684 
CVR 1 25.3756 445.1115 0.364934 
CVR 2 1.982277 6.688098 2.013535 
IFC Application on 
the Forearm (n = 4) 
   
CBF 1 68.73909 -89.7606 117.8071 
CBF 2 20.54841 37.41265 5.370384 
SBP 3.632479 6.452991 3.076923 
DBP -4.3794 1.947623 -2.26673 
HR 2.255727 8.625526 -1.6129 
MAP -0.92894 4.044313 0 
CVR 1 -10.8726 1518.964 -43.7508 
CVR 2 -16.7931 -20.5259 -2.40704 
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Appendix G: Statistical Analysis 
Table G.1: Two-way Repeated Measures ANOVA P-values for Hemodynamic Endpoints 
 Baseline Exercise  Occlusion Recovery 
CBF 1 - 0.5962 0.0525 0.2257 
CBF 2 - 0.4950 0.4691 0.9333 
SBP - 0.5827 0.7223 0.8479 
DBP - 0.4988 0.9417 0.8843 
HR - 0.4601 0.9878 0.2911 
MAP - 0.2122 0.8725 0.7789 
CVR 1 - 0.8997 0.3380 0.3474 
CVR 2 - 0.3535 0.2601 0.6502 
Pain Intensity 0.0817 0.0654 0.2176 0.3325 
 
 P-value 
Reperfusion Time 0.039* 
* Dunnett’s Test Comparison: IFC on Back significantly different from control 
 
